Check for updates

OPEN ACCESS

EDITED BY Hongbo Li, Shaanxi University of Science and Technology, China

REVIEWED BY Claudio Frezza, Università Link Campus, Italy Changfu Wang, Guangdong Pharmaceutical University, China

*CORRESPONDENCE Xiongyu Meng, mengxiongyu@zcmu.edu.cn Lupin Qin, lpqin@zcmu.edu.cn Qiming Zhao, gmzhao@zcmu.edu.cn

 $^{\rm t}{\rm These}$ authors have contributed equally to this work

RECEIVED 19 September 2024 ACCEPTED 26 November 2024 PUBLISHED 19 December 2024

CITATION

Jiang Z, Zhang C, Yu X, Wang K, Sang Z, Gong W, Zhang Q, Meng X, Qin L and Zhao Q (2024) Traditional utilization, botany, phytochemistry, pharmacology, pharmaceutical analysis, processing and application of the seeds of *Herpetospermum pedunculosum* (Ser.) C.B. Clarke: a comprehensive review. *Front. Pharmacol.* 15:1498768. doi: 10.3389/fphar.2024.1498768

COPYRIGHT

© 2024 Jiang, Zhang, Yu, Wang, Sang, Gong, Zhang, Meng, Qin and Zhao. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Traditional utilization, botany, phytochemistry, pharmacology, pharmaceutical analysis, processing and application of the seeds of *Herpetospermum pedunculosum* (Ser.) C.B. Clarke: a comprehensive review

Zhixia Jiang[†], Chuang Zhang[†], Xinran Yu[†], Kaiyi Wang, Zhenqi Sang, Wan Gong, Qiaoyan Zhang, Xiongyu Meng^{*}, Lupin Qin^{*} and Qiming Zhao^{*}

College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China

The seed of Herpetospermum pedunculosum (Ser.) C.B. Clarke, known in Chinese as Bo-Leng-Gua-Zi and in Tibetan as Sejimedo, are here abbreviated as H. pedunculosum seeds. Herpetospermum pedunculosum seeds is a traditional Chinese medicine for protecting the liver, clearing heat, and detoxifying. A total of 125 chemical metabolites of H. pedunculosum seeds are found, including lignans, fatty acids, terpenes, coumarins, and others. The pharmacological activities of H. pedunculosum seeds are mainly in hepatoprotective, antioxidant, anti-cancer cells, and anticholestatic effects. In clinical application, it is mainly used in combination with other traditional Chinese medicines to play a key role in treating the liver disease. This paper gives a systematic review of above research aspects, proposes the potential limitations and put forward plausible solutions. Relevant literatures were searched in PubMed, Web of Science and Chinese National Knowledge Infrastructure with Herpetospermum as the key word. A number of studies have shown that H. pedunculosum seeds exert excellent hepatoprotective effects by acting on NF- κ B, TGF- β , and Keap1-Nrf2 signaling pathways, which provide a solid base for its clinic application. However, more research is needed to explore the standard cultivation and guality evaluation of H. pedunculosum seeds and systematical structure-activity relationship of its active metabolites.

KEYWORDS

Herpetospermum pedunculosum (Ser.) C.B. Clarke, phytochemistry, pharmacological activity, liver protection, lignan

1 Introduction

With the continuous development of various drugs, phytomedicines with fewer side effects and significant effects are gradually attracting people. Especially for some effective ethnodrugs, further development of their hidden medicinal value through in-depth research is increasingly popular and desirable. *Herpetospermum pedunculosum* (Ser.) C.B. Clarke (*H.*



FIGURE 1 Flower (A), leaf (B), fruit (C) and seed (D) of *Herpetospermum pedunculosum* (Ser.) C.B. Clarke.





pedunculosum) is mainly distributed in several high-altitude areas such as Tibet, Yunnan, India and Nepal. As the main medicinal part of *H. pedunculosum* (Ser.) C.B. Clarke, *H. pedunculosum* seeds are traditional Tibetan drug, which have traditional effects of clearing heat and softening liver. At the same time, *H. pedunculosum* seeds are also the core ingredient of clinical traditional Chinese





prescriptions, such as Jiuwei Zhangya Pill (for treating cholecystitis), Wuwei Jinse Pill (for treating jaundice hepatitis), and Songshi pill (for treating hepatitis and liver fibrosis). Modern studies have shown that *H. pedunculosum* seeds contain a variety of chemical metabolites, including lignans, coumarins, terpenes, etc. (Xu, 2012), and have shown a variety of pharmacological activities, including liver protection, antioxidant, anti-tumor, and anti-cholestasis effects (Gong, 2012; Shen et al., 2015).







The excellent pharmacological effects and particular characteristics of *H. pedunculosum* seeds undoubtedly deserve systematical induction and summary, which is hardly reported to the best of our knowledge. Therefore, we investigated relevant literatures in Web of Science, PubMed and CNKI with Herpetospermum as the key word, and focused on the literatures of the *H. pedunculosum* seeds with excluding that on other parts, such as stem, leaf and flesh. Based on these literatures, this paper comprehensively reviews the traditional use, botany, chemical metabolites, pharmacological effects, pharmaceutical analysis, processing and application in Chinese herbal prescriptions of *H. pedunculosum* seeds, which can provide scientific basis for further research and promote the potential for development.

2 Traditional uses

As a classic Tibetan medicine, *H. pedunculosum* seeds often used in the treatment of Tri-pa (a disease be traditionally characterized by diffusion of bile, disorders of the blood-heat, and yellow color in the muscles and eyes), which was first recorded in Yue Wang Yao Zhen (《月王药诊》) in the early 8th century. At the same time, in the middle of the 8th century, Tara Materia Medica (《度母本草》, Shivatso) recorded that *H. pedunculosum* seeds can treat heat disease, and bacon disease (diseases caused by the combination of food accumulation and cold). Beside these, Si Bu Yi Dian (《四部 医典》, Yutog Yontan Gonpo), written and revised during the late 8th to 12th century, further proposed that *H. pedunculosum* seeds

No.	Name	Molecular formula	Extract	Separation method	ldentification method	References
			Ligna	an		
1	Herpetriol	$C_{30}H_{34}O_9$	Ethyl alcohol	_	UV, IR,MS, ¹ H-NMR, ¹³ C-NMR	Kaouadji et al. (1979)
2	Herpetetrol	$C_{40}H_{44}O_{12}$	Ethyl alcohol	_	UV, MS, ¹ H-NMR, ¹³ C-NMR	Kaouadji et al. (1979)
3	Herpepentol	$C_{50}H_{54}O_{15}$	МеОН	_	MS, ¹ H-NMR, ¹³ C-NMR	Kaouadji and Pieraccini (1984a)
4	Herpetetradione	$C_{40}H_{42}O_{12}$	MeOH	_	MS, ¹ H-NMR, ¹³ C-NMR	Kaouadji and Favre-Bonvin (1984a)
5	Herpetetrone	$C_{40}H_{42}O_{13}$	MeOH	Polyamide CC6 and sephadex LH-20, chromatography	UV, IR, MS, ¹ H-NMR	Kaouadji et al. (1987)
6	Herpetrione	$C_{30}H_{32}O_{10}$	Ethyl alcohol	_	MS, ¹ H-NMR, ¹³ C-NMR	Kaouadji and Jean (1983)
7	Herpetone	$C_{29}H_{30}O_{9}$	Ethyl alcohol	Silica gel column chromatography, preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR	Zhang et al. (2006)
8	Herpetol	$C_{20}H_{20}O_{6}$	Ethyl alcohol	—	UV, MS, ¹ H-NMR, ¹³ C-NMR	Kaouadji and Pieraccini (1984a)
9	Dehydrodiconiferyl alcohol	$C_{20}H_{22}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	UV, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
10	Herpetosin B	$C_{20}H_{22}O_7$	Ethyl acetate	Silica gel column chromatography	UV, IR, MS, ¹³ C-NMR, ¹ H-NMR	Xu (2012)
11	Herpetal	$C_{20}H_{18}O_6$	Ethyl acetate	_	UV, ¹ H-NMR, ¹³ C-NMR	Kaouadji et al. (1978)
12	Herpetotriol	$C_{30}H_{32}O_9$	Ethyl acetate	_	UV, ¹ H-NMR, ¹³ C-NMR	Kaouadji et al. (1978)
13	Herpepropenal	$C_{30}H_{30}O_{10}$	Ethyl acetate	Silica gel column chromatography, RPC18, HPLC	MS, ¹³ C-NMR, ¹ H-NMR, DEPT, HMBC, COSY, HSQC, NOESY	Yang et al. (2010)
14	7,8'-didehydlroherpetotriol	C ₃₀ H ₃₂ O ₉	Ethyl acetate	Reversed phase silica gel column chromatography, Preparation for HPLC Chromatography	UV, IR, MS, ¹ H-NMR, ¹³ C-NMR	Xu (2012)
15	(7S,8R,7'R,8'S)-7'-[7'-ethoxyl-7'-(4'- hydroxyl-3'-methoxylphenyl)]methyl-7- (4-hydroxyl-3-methoxylphenyl)-8- hydroxymethyl-tetrahydrofuran	$C_{22}H_{28}O_7$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi- preparative HPLC	UV, IR, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
16	(7S,8R)-threo-1'-[3'-hydroxy-7-(4- hydroxy-3-methoxyphenyl)-8- hydroxymethyl-7,8-dihydrobenzofuran] acrylaldehyde	$C_{19}H_{18}O_6$	Ethyl aceta	Normal phase silica gel column chromatography, MPLC, semi- preparative HPLC	UV, IR, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
17	(–)-Tanegool-7′-methyl etherl	$C_{21}H_{26}O_7$	Ethyl acetate	Silica gel column chromatography, sephadex LH-20	MS, ¹ H-NMR, ¹³ C-NMR	Zhou (2014)
18	Herpetin	$C_{30}H_{34}O_9$	Ethyl acetate	Silica gel column chromatography, Rp-Si -gel, semi- preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR	Yuan et al. (2005)

TABLE 1 Metabolites extracted from *Herpetospermum pedunculosum* seeds.

TABLE 1 (Continued) Metabolites extracted from Herpetospermum pedunculosum seeds.

No.	Name	Molecular formula	Extract	Separation method	ldentification method	References
19	Lariciresino	$C_{20}H_{24}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	UV, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
20	(+)-(7'\$,7''\$,8'R,8''R)-4,4',4''- Trihydroxy-3,5',3''-trimethoxy-7-oxo-8- ene[8-3',7'-O-9'',8'-8'',9'-O-7''] lignoid	C ₃₀ H ₃₀ O ₉	Petroleum ether	Silica gel column chromatography, preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR, 1H-1H COSY, HMQC, HMBC	Yu et al. (2014)
21	Ent-isolariciresinol	$C_{20}H_{24}O_{6}$	Ethyl acetate	Silica gel column chromatography, MPLC, semi-preparative HPLC	UV, MS, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
22	Herpetenol	$C_{20}H_{22}O_6$	Ethyl acetate	Silica gel column chromatography	UV, IR, MS, ¹ H-NMR, ¹³ C-NMR	Wang (2005)
23	Herpetfluorenone	$C_{16}H_{14}O_{6}$	Ethyl acetate	Silica gel column chromatography, sephadex LH-20	MS, ¹ H-NMR, ¹³ C-NMR	Gong et al. (2016
24	(1S)-4hydroxy-3-[2-(4-hydroxy-3- methoxy-phenyl)-1-hydroxymethyl2- oxo-ethyl]-5-methoxy-benzaldehyde	$C_{18}H_{18}O_7$	Petroleum ether	Silica gel column chromatography, RPC18, sephadex LH-20	MS, IR, ¹ H-NMR, ¹³ C-NMR, ¹ H- ¹ H COSY, HMQC, HMBC	Yu et al. (2014)
25	Hedyotol A	$C_{30}H_{32}O_9$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
26	Picrasmalignan	$C_{30}H_{30}O_9$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
27	Balanophonin	$C_{20}H_{20}O_{6}$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
28	1-Propanone, 3-hydroxy-1-(4-hydrpxy- 3-methoxyphenyl)-2-[4-(3-hydroxy-1- propen-1-yl)-2-methoxyphenoxy]	$C_{21}H_{24}O_6$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
29	Erythro-guaiacylglycerol-b-coniferyl ether	$C_{20}H_{24}O_7$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
30	Threo-guaiacylglycerol- b-coiferyl ether	$C_{20}H_{24}O_7$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
31	(7R,8S)-Dehydrodiconiferyl alcohol γ'- methyl ether	$C_{21}H_{24}O_{6}$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
32	3-Benzofuranmethanol, 2, 3-dihydro-2- (4-dydroxy-3-methoxypenyl)-7- methoxy-5-(3-methoxyl-1-propenyl)- ,[28-[2a,3b, 5(E)]]-(9CI)	$C_{21}H_{24}O_6$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
33	Evofolin-B	$C_{17}H_{18}O_6$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
34	1-Propanon, 3-hydroxy-1-(2-hydrpxy-5- methoxyphenyl)-2-(4-hydroxy-3- methoxyphenyl)-	$C_{20}H_{24}O_7$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
35	Herpetatol A	$C_{19}H_{18}O_5$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
36	Herpetatol B	$C_{19}H_{16}O_5$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)

No.	Name	Molecular formula	Extract	Separation method	ldentification method	References
37	Herpetatol C	$C_{20}H_{22}O_7$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
38	Herpetatol D	C ₃₁ H ₃₂ O ₉	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
39	Herpetatol E	$C_{30}H_{30}O_9$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
40	Herpetatol F	C ₂₉ H ₂₈ O ₈	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
41	Herpetatol G	$C_{29}H_{28}O_8$	Ethyl acetate	Silica gel/gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
42	(–)-pinoresinol monomethyl ether	$C_{21}H_{24}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
43	epipinoresinol	$C_{20}H_{22}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	UV, MS, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
44	(+)-pinoresinol	$C_{20}H_{22}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
45	(+)-menbrine	$C_{21}H_{24}O_5$	Ethyl acetate	Normal phase silica gel column chromatography, semi-preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
46	cinncassins D	C ₂₈ H ₂₈ O ₉	Ethyl acetate	Normal phase silica gel column chromatography, semi-preparative HPLC	MS, UV, IR, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
47	(7R,7'R,7"R,85,8'S,8"S)-4',4"- dihydroxy-3,3',3",5-tetramethoxy-7,9': 7',9-diepoxy-4,8"-oxy-8,8'- sesqoineolignan-7",9"-diol	C ₃₁ H ₃₆ O ₁₁	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, sephadex LH-20, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
48	3-Benzofuranmethanol-2,3-dihydro-2- (4-hydroxy-3-methoxyphenyl)-4-: methoxy-6-[tetra-hydro-2-(3-hydroxy- 4-methoxyphenyl)-3-methanol]-2- furanmethyl	$C_{31}H_{36}O_8$	Ethyl acetate	Normal phase silica gel column chromatograpy	MS, ¹ H-NMR, ¹³ C-NMR	Yuan et al. (2006b
49	Ehletianol C	$C_{30}H_{36}O_{10}$	Ethyl acetate	Normal phase silica gel column chromatography, semi-preparative HPLC	MS, UV, ¹ H-NMR, ¹³ C-NMR	Ma (2020)
50	Herpetosiol G	$C_{20}H_{22}O_5$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC	Ma (2020)
51	Herpetosiol H	$C_{23}H_{30}O_8$	Ethyl acetate	Normal phase silica gel column chromatography, sephadex LH-20, semi- preparative HPLC	UV, IR, MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC, COSY, NOESY	Ma (2020)
52	Herpetosiol I	$C_{30}H_{34}O_{10}$	Ethyl acetate	Normal phase silica gel column chromatography, sephadex LH-20, semi- preparative HPLC	UV, IR, MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC, COSY, NOESY	Ma (2020)

No.	Name	Molecular formula	Extract	Separation method	ldentification method	References
53	Herpetosiol J	$C_{23}H_{24}O_9$	Ethyl acetate	Normal phase silica gel column chromatography, semi-preparative HPLC	UV, MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC, COSY, NOESY	Ma (2020)
54	Herpetosiol K	$C_{30}H_{30}O_9$	Ethyl acetate	Normal phase silica gel column chromatography, semi-preparative HPLC	UV, IR, MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC, COSY, NOESY	Ma (2020)
55	Herpetosiol L	$C_{19}H_{18}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	UV, MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC, COSY, NOESY	Ma (2020)
56	Herpetosiol M	C ₂₀ H ₂₀ O ₇	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC	Ma (2020)
57	Herpetosiol N	$C_{32}H_{38}O_{11}$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, sephadex LH-20, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC, COSY, NOESY	Ma (2020)
58	Phyllanglaucin B	$C_{30}H_{34}O_9$	Ethyl acetate	Normal phase silica gel column chromatography, recrystallization	MS, ¹ H-NMR, ¹³ C-NMR	Huang et al. (2021)
59	Buddlenol E	C ₃₂ H ₃₈ O ₁₀	Ethyl acetate	Normal phase silica gel column chromatography, sephedax LH-20, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Huang et al. (2021)
60	Spathulated	$C_{30}H_{34}O_9$	Ethyl acetate	_	HPLC	Wei et al. (2020)
61	Threo-buddlenol E	$C_{31}H_{36}O_{11}$	Ethyl acetate	_	HPLC	Wei et al. (2020)
62	Picrasmalignan A	C ₂₉ H ₂₈ O ₉	Ethyl acetate	_	HPLC	Wei et al. (2020)
63	9,3'-Dimethoxyhierochin A	$C_{21}H_{24}O_6$	Ethyl acetate	_	HPLC	Wei et al. (2020)
64	Sesquilignan	$C_{30}H_{34}O_9$	Ethyl acetate	_	HPLC	Yuan et al. (2019
65	Herpedulin A	$C_{50}H_{52}O_{16}$	Ethyl acetate	Silica gel column chromatography, preparative TLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC	Meng et al. (2022
66	Herpedulin B	$C_{30}H_{34}O_{10}$	Ethyl acetate	Silica gel column chromatography, sephadex LH-20, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC	Meng et al. (2022
67	Herpedulin C	$C_{31}H_{36}O_{11}$	Ethyl acetate	Silica gel column chromatography, MPLC, sephadex LH-20, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, ¹ H- ¹ H COSY, HSQC, HMBC, CD spectrum	Meng et al. (2022
68	Herpedulin D	C ₃₁ H ₃₆ O ₁₁	Ethyl acetate	Silica gel column chromatography, MPLC, sephadex LH-20, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, ¹ H- ¹ H COSY, HSQC, HMBC, CD spectrum	Meng et al. (2022
69	Herpedulin E	$C_{30}H_{30}O_9$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC, CD spectrum	Meng et al. (2022

TABLE 1	ABLE 1 (Continued) Metabolites extracted from Herpetospermum pedunculosum seeds.							
No.	Name	Molecular formula	Extract	Separation method	Identification method	References		
70	Herpedulin F	$C_{32}H_{38}O_{11}$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HSQC, COSY	Meng et al. (2022)		
71	Herpedulin G	$C_{30}H_{32}O_{11}$	Ethyl acetate	Silica gel column chromatography, MPLC, sephadex LH-20, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HSQC, CD spectrum	Meng et al. (2022)		
72	Herpedulin H	$C_{30}H_{32}O_{11}$	Ethyl acetate	Silica gel column chromatography, MPLC, sephadex LH-20, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, CD spectrum	Meng et al. (2022)		
73	Herpedulin I	$C_{30}H_{32}O_{11}$	Ethyl acetate	Silica gel column chromatography, MPLC, sephadex LH-20, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, CD spectrum	Meng et al. (2022)		
74	Herpedulin J	$C_{23}H_{24}O_9$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HSQC, NOSY, HMBC	Meng et al. (2022)		
75	Herpedulin K	$C_{30}H_{26}O_9$	Ethyl acetate	Silica gel column chromatography, recrystalization	MS, ¹ H-NMR, ¹³ C-NMR, HSQC, HMBC	Meng et al. (2022)		
76	Herpedulin L	$C_{23}H_{30}O_8$	Ethyl acetate	Silica gel column chromatography, sephadex LH-20, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC, NOESY, CD spectrum	Meng et al. (2022)		
77	Herpedulin M	C ₁₉ H ₁₈ O ₆	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HSQC, ¹ H- ¹ HCOSY, HMBC	Meng et al. (2022)		
78	Herpedulin N	$C_{20}H_{20}O_7$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Meng et al. (2022)		
79	Herpedulin O	$C_{20}H_{22}O_5$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, HMBC, CD spectrum	Meng et al. (2022)		
80	Herpedulin P	$C_{19}H_{20}O_5$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR CD spectrum	Meng et al. (2022)		
			Fatty a	cids				
81	Palmitic acid	C ₁₆ H ₃₂ O ₂	Petroleum ether	_	GC-MS	Liu et al. (2005a)		
82	Oleic acid	$C_{18}H_{34}O_2$	Petroleum ether	_	GC-MS	Liu et al. (2005a)		
83	Stearic acid	$C_{18}H_{34}O_2$	Petroleum ether	_	GC-MS	Liu et al. (2005a)		

T.

(Continued on following page)

Zhang et al. (2004)

Dong et al. (2019)

Dong et al. (2019)

GC-MS

MS, ¹H-NMR, ¹³C-NMR

MS, ¹H-NMR, ¹³C-NMR

84

85

86

Linoleic acid

Linolenic acid

Trilinolein

Petroleum

ether Petroleum

ether

Petroleum

ether

_

Normal phase silica gel

column chromatography,

semi- preparative HPLC

Normal phase silica gel column chromatography, preparative HPLC

 $C_{18}H_{32}O_2$

 $C_{18}H_{30}O_{2} \\$

C57H98O6

IADLE I	(Continued) Metabolites extracted fr	om Herpetosperm	ит реаинси	osum seeas.		
No.	Name	Molecular formula	Extract	Separation method	Identification method	References
87	9-Octadecenoic acid	$C_{18}H_{34}O_2$	Petroleum ether	_	GC-MS	Liu et al. (2005b)
88	Octadecanoic acid	$C_{18}H_{36}O_2$	Petroleum ether	_	GC-MS	Liu et al. (2005a)
89	cis-5-Dodecaenoic acid	$C_{12}H_{22}O_2$	Petroleum ethe	Silica gel column chromatography	MS, ¹ H-NMR, ¹³ C-NMR	Chen (2020)
90	Dodecanoic acid	C12H24O2	Ethyl acetate	Silica gel column chromatography	MS, ¹ H-NMR, ¹³ C-NMR	Xu, (2012)
91	10-Eicossenoic acid	C20H38O2	Ethyl acetate	Silica gel column chromatography, sephadex LH-20	MS, ¹ H-NMR, ¹³ C-NMR	Xu, (2012)
			Terpen	oids		
92	Neocucurbitacin D	$C_{31}H_{44}O_8$	90% EtOH	Silica gel column chromatography, sephadex LH-20, RP-HLPC	MS, IR, ¹ H-NMR, ¹³ C-NMR, HMBC, NOESY	Jiang et al. (2020)
93	Cucurbitacin E	$C_{32}H_{44}O_8$	90% EtOH	Silica gel column chromatography, sephadex LH-20, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Jiang et al. (2020)
94	Cucurbitacin D	$C_{30}H_{44}O_7$	90% EtOH	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Jiang et al. (2020)
95	Cucurbitacin B	$C_{31}H_{44}O_8$	90% EtOH	Silica gel column chromatography, sephadex LH-20, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Jiang et al. (2020)
96	Cucurbitacin I	$C_{30}H_{46}O_7$	90% EtOH	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR	Jiang et al. (2020)
97	23, 24-Dihydroisocucurbitacin B	$C_{32}H_{48}O_8$	90% EtOH	Silica gel column chromatography, sephadex LH-20, RP-HLPC	MS, ¹ H-NMR, ¹³ C-NMR	Jiang et al. (2020)
98	Cucurbitacin M	$C_{30}H_{44}O_6$	Ethyl acetate	Normal phase silica gel column chromatography, MPLC, semi-preparative HPLC	MS, ¹ H-NMR, ¹³ C-NMR, DEPT, HMBC, ¹ H-H COSY	Ma (2020)
99	Herpetosin A	$C_{22}H_{30}O_6$	Ethyl acetate	Silica gel column chromatography	UV, IR, MS, ¹³ C-NMR, ¹ H-NMR	Xu (2012)
100	Cucurbitacin L	$C_{30}H_{44}O_7$	Ethyl acetate	Silica gel column chromatography, Sephadex LH-20	MS, ¹ H-NMR	Dai et al. (2017)
101	Oleanic acid	$C_{30}H_{48}O_3$	Ethyl acetate	Silica gel column chromatography, Sephadex LH-20	MS, ¹ H-NMR	Dai et al. (2017)
			Couma	arins		·
102	Herpetolide A	$C_{16}H_{14}O_{6}$	Ethyl acetate	Silica gel column chromatography, recrystallization	MS, IR, ¹ H-NMR, ¹³ C-NMR, HMBC, NOESY, DEPT, HMQC	Zhang et al. (2008)
103	Herpetolide B	$C_{16}H_{12}O_{6}$	Ethyl acetate	Silica gel column chromatography, recrystallization	MS, IR, ¹ H-NMR, ¹³ C-NMR, HMBC	Zhang et al. (2008)

TABLE 1 (Continued) Metabolites extracted from Herpetospermum pedunculosum seeds.

TABLE 1 (Continued) Metabolites extracted from Herpetospermum pedunculosum seeds.

No.	Name	Molecular formula	Extract	Separation method	ldentification method	References
104	Herpetosperin A	C ₂₂ H ₂₄ O ₁₁	Ethyl acetate	Silica gel column chromatography, ODS silica gel CC, semi-preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR, HMBC	Xu et al. (2015)
105	Herpetosperin B	$C_{22}H_{24}O_{11}$	Ethyl acetate	Silica gel column chromatography, ODS silica gel CC, semi-preparative HPLC	MS, IR, ¹ H-NMR, ¹³ C-NMR, HMBC	Xu et al. (2015)
106	Herpetospin C	$C_{23}H_{26}O_{10}$	Ethyl acetate	Reverse phase silica gel column chromatography	UV, IR, MS, ¹³ C-NMR, ¹ H-NMR	Xu (2012)
107	Herpetolide H	C ₁₉ H ₁₆ O ₆	Ethyl acetate	Normal phase silica gel column chromatography, recrystallization	MS, ¹ H-NMR, ¹³ C-NMR	Huang et al. (2021
108	Herpetospin D	$C_{22}H_{22}O_{11}$	Ethyl acetate	Normal phase silica gel column chromatography, recrystallization	MS, ¹ H-NMR, ¹³ C-NMR	Xu (2012)
			Othe	ers		
109	Arginine	$C_6H_{14}N_4O_2$	HCl	_	HITACHI 835-50 High-speed amino acid analyzer, XDY-I atomic fluorescence spectrometer	Li et al. (2005)
110	Histidine	$C_6H_9N_3O_2$	HCl	_	HITACHI 835-50 High-speed amino acid analyzer, XDY-I atomic fluorescence spectrometer	Li et al. (2005)
111	Lysine	$C_6H_{14}N_2O_2$	HCl	_	HITACHI 835-50 High-speed amino acid analyzer, XDY-I atomic fluorescence spectrometer	Li et al. (2005)
112	Leucine	C ₆ H ₁₃ NO ₂	HCl	_	HITACHI 835-50 High-speed amino acid analyzer, XDY-I atomic fluorescence spectrometer	Li et al. (2005)
113	Isoleucine	C ₆ H ₁₃ NO ₂	HCl	_	HITACHI 835-50 High-speed amino acid analyzer, XDY-I atomic fluorescence spectrometer	Li et al. (2005)
114	Tryptophan	$C_{11}H_{12}N_2O_2$	HCl	_	HITACHI 835-50 High-speed amino acid analyzer, XDY-I atomic fluorescence spectrometer	Li et al. (2005)
115	Kaempferitrin	$C_{27}H_{30}O_{14}$	Ethyl acetate	Reversed phase silica gel column chromatography, semi-preparative HPLC	UV, IR, ¹ H-NMR, ¹³ C-NMR	Fan et al. (2016)
116	3′-Hydroxydaidzein	$C_{15}H_{10}O_5$	Ethyl acetate	Silica gel column chromatography, semi- preparative HPLC	MS, ¹ H-NMR	Dai et al. (2017)
117	Stigmasterol	C ₂₉ H ₄₈ O	Ethyl acetate	Silica gel column chromatography, recrystalization	MS, ¹ H-NMR, ¹³ C-NMR	Liu et al. (2010)
118	β-Stigmasterol	C ₂₉ H ₄₈ O	Ethyl acetate	Silica gel column chromatography, Sephadex LH-20	MS, ¹ H-NMR, ¹³ C-NMR	Gong (2013)
119	Spinasterol glucoside	$C_{35}H_{56}O_{6}$	Ethyl acetate	Silica gel column chromatography, recrystalization	UV, IR, MS, ¹ H-NMR, ¹³ C-NMR	Liu et al. (2010)

No.	Name	Molecular formula	Extract	Separation method	ldentification method	References
120	Arbutin, 1-acetate	$C_{14}H_{18}O_8$	Ethyl acetate	Reversed phase silica gel column chromatography	Uv, IR, MS, ¹ H-NMR, ¹³ C-NMR	Hu (2016)
121	Herpetolide C	$C_{16}H_{14}O_{6}$	Petroleum ether	Silica gel column chromatography, sephadex LH-20, smi-preparative HPLC	UV, IR, MMS, ¹ H-NMR, ¹³ C-NMR, HMQC, HMBC	Fan et al. (2016)
122	Eicosanoic acid, 2-propenyl ester	$C_{23}H_{44}O_2$	Ethyl acetate	Silica gel column chromatography, sephadex LH-20	MS, ¹ H-NMR	Dai et al. (2017)
123	3-Dodecen-1-yne	C ₁₂ H ₂₀	petroleum ether	_	GC-MS	Liu et al. (2005)
124	2,6,10,14,18,22-Tetracosahexaen	C ₂₄ H ₃₈	petroleum ether	_	GC-MS	Zhang et al. (2004)
125	Herpecaudin	$C_{17}H_{22}O_4$	Ethyl acetate	RPHPLC, silica gel column chromatography, RP-18, sephadex LH-20	MS,1H-NMR,13C-NMR, HMBC, NOESY, CD spectrum, X-ray	Jiang et al. (2016)

TABLE 1 (Continued) Metabolites extracted from Herpetospermum pedunculosum seeds.

can remove the heat of the lower organs. In addition, it supplemented the bitter taste of H. pedunculosum seeds. Jingzhu Materia Medica (《晶珠本草》, Dema Tenpe Nyima), written in 1840, proposed that H. pedunculosum seeds could treat Tri-pa in the viscera. Diqing Tibetan medicine (《迪庆藏药》, Yang and Chu cheng) and Chinese Tibetan medicine (《中华藏本草》Luo, 1997) supplement recorded its effects of treating liver and gallbladder heat and indigestion, which was also supported by the record of Chinese Materia Medica (《中华本草》, National Administration of Traditional Chinese Medicine). In 2015, the "Interpretation of Tibetan Medicine Jinsui Materia Medica" (《藏药金穗本草诠释》), Gama Qupei) concluded that H. pedunculosum seeds could treat the liver and gallbladder diseases of the Tri-pa type. In summary, H. pedunculosum seeds have been used as its prototype medicine for over 13 centuries, and its effects on protecting the liver and treating indigestion have gained tremendous application as recorded in traditional medical books.

3 Botany

Herpetospermum pedunculosum (Ser.) C. B. Clarke, is usually harvested at around October, and adapts to grow on warm, humid subtropical roadsides, hillsides, shrubland, and forest edges at the altitude of 2,300–3,500 m (Flora Reipublicae Popularis Sinicae Commission, 1983) and its botanical organs including the flower, leaf, fruit and seed were shown in Figures 1A–D. As displayed in Figure 1D, *H. pedunculosum* seeds is slightly oblong with uneven carving and the surface from brown to black brown. One end of *H. pedunculosum* seeds has triangular protrusions, and the other end is tapered, slightly wedge-shaped and slightly concave in the center (Chinese Materia Medica Commission, 1998). The further investigation of *H. pedunculosum* seeds characters and sources can enhance the standardization of commercial *H. pedunculosum* seeds and is of great significance in cultivating it.

4 Phytochemistry

The chemical metabolites of *H. pedunculosum* seeds are reported to include lignans, fatty acids, terpenoids, and coumarins. The other metabolites such as amino acids, alkaloids, and flavones were also discussed. Details can be found in Figures 2–6 and Table 1.

4.1 Lignans

As collected in Figure 2 and summarized in Figure 3, lignans in *H. pedunculosum* seeds can be mainly divided into benzofurans, tetrahydrofurans and furofuran. In benzofuran lignan such as dehydrodiconiferyl alcohol (9) and herpetotriol (12), the benzene ring is linked to the side chain to form the furan oxygen ring (Figure 2; Table 1). In furfuran lignan, bimolecular phenylpropanin side chains are connected to form a *bis*-tetrahydrofuran ring, such as herpetetradione (4), herpetetrone (5) and herpetrione (6). Tetrahydrofurans lignans can be further divided into three types with 7-O-7' (a), 7-O-9' (b), and 9-O-9' (c) structures (Figure 2). The tetrahydrofuran of 7-O-9' is predominant in *H. pedunculosum* seeds, represented by herpetriol (1) and herpetetrol (2). Beside above three main lignan types, *H. pedunculosum* seeds also contains dibenzylbutane (chemicals of 29 and 30) as shown in Figure 2.

4.2 Fatty acids

It has been found that *H. pedunculosum* seeds contain various fatty acids (81-91, Figure 4; Table 1), with comparatively greater concentrations of linoleic (84) and linolenic acid (85) (Zhao et al., 2009). Oleic (82), palmitic (81), and linoleic acids (84) are reported to be physiologically active in decreasing blood cholesterol levels and alleviating the formation of cholesterol in the vascular wall

Liver disease	Extract/ Compound	Animal/cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
Hepatic fibrosis	Ethyl acetate (EAEHPS)	Animal: Sprague-Dawley rats (male) Model: Induction of CCl ₄ (50%, 3 mL/kg) Treatment: EAEHPS (1 and 3 g/kg) for 6 weeks Positive control: Silymarin (0.1 g/kg) for 6 weeks	ALT \downarrow , AST \downarrow , TNF-a \downarrow , IL-1 β \downarrow , IL-6 \downarrow , TGF- β I \downarrow , NF- κ B 65 \downarrow , I κ Ba \uparrow , Smad 3 \uparrow . (Compared with the model group) HA/µg L^-1; 49.35 \pm 5.26, 75.37 \pm 22.65, 61.27 \pm 8.46 (L) 54.97 \pm 8.63 (H), 39.94 \pm 12.61; LN/µg L^-1; 73.55 \pm 13.06, 131.74 \pm 20.94, 110.38 \pm 27.89 (L), 108.78 \pm 6.61 (H), 112.87 \pm 16.94; PCIII/µg L^-1; 75.57 \pm 5.11, 117.65 \pm 29.45, 98.38 \pm 10.28 (L), 93.11 \pm 10.19 (H), 88.60 \pm 6.92; CoIIV/µg L ⁻¹ ; 58.75 \pm 23.14, 78.15 \pm 14.70, 54.86 \pm 16.03 (L), 46.31 \pm 10.88 (H), 56.75 \pm 15.14	Feng et al. (2018a)
	Chloroform	Animal: Sprague-Dawley rats (male) Model: Induction of CCl ₄ (50%, 3 mL/kg) Treatment: 1 and 3 g/kg) for 10 weeks	GPT↓, GOT↓, TBIL↓, CP↓, HA↓, LN↓, PCIII↓, ColIV↓, TBA↓, MDA↓, CAT↑, SOD↑, ALB↑.(Compared with the model group)	Li et al. (2019)
Hepatic fibrosis	Chloroform	Animal: KM mice Model: Induction of CCl ₄ (1%, 5 mL/kg) Treatment: 10 (L), 30 (M), 60 (H) g/kg for 1 week	$ \begin{array}{l} ALT/U'L^{-1}\!\!: 26.07 \pm 3.23, 121.04 \pm 9.8, 53.99 \pm \\ 3.21 (L), 37.25 \pm 9.80 (M), 30.40 \pm 2.44 (H),/); \\ AST/U'L^{-1}\!: 66.09 \pm 8.99, 231.84 \pm 18.32, 139.67 \pm \\ 13.98 (L), 126.63 \pm 8.53 (M), 99.63 \pm 36.89 (H),/; \\ MDA/nmol'mg^{-1}\!: 6.35 \pm 1.49, 11.74 \pm 1.07, \\ 8.80 \pm 1.87 (L) 7.77 \pm 0.32 (M) 7.01 \pm 0.48 (H),/; \\ SOD/U'mg^{-1}\!: 45.20 \pm 6.00, 22.80 \pm 4.3, 30.99 \pm \\ 2.80 (L), 41.06 \pm 1.73 (M), 36.91 \pm 7.89 (H),/; \\ Caspase-3:/, 0.1674 \pm 0.0061, 0.1555 \pm 0.0010 (L), 0.1356 \pm 0.0099 (M), 0.1096 \pm 0.0083 (H),/ \end{array} $	Jiang (2011)
Liver protection	Water	Animal: KM mice Model: Induction of CCl ₄ (1%, 5 mL/kg) Treatment: 10 (L), 30 (M), 60 (H) g/kg for 1 week	$ \begin{array}{l} ALT/U!L^{-1}\!:26.07\pm 3.23,121.04\pm 9.8,72.16\pm 4.9\\ (L),59.59\pm 9.81\ (M),54.92\pm 7.03\ (H),',AST/\\ U!L^{-1}\!:66.09\pm 8.99,231.84\pm 18.32,185.29\pm 19.63\\ (L)172.25\pm 12.61\ (M),160.15\pm 12.91\ (H),';\\ MDA/nmolmg^{-1}\!:6.35\pm 1.49,11.74\pm 1.07,\\ 8.80\pm 1.87\ (L),7.77\pm 0.32\ (M),7.01\pm 0.48\ (H),';\\ SOD/Umg^{-1}\!:45.20\pm 6.00,22.80\pm 4.3,30.99\pm 2.80\ (L),41.06\pm 1.73\ (M),36.91\pm 7.89\ (H),';\\ Caspase-3:/,0.1674\pm 0.0061,0.1505\pm 0.0062\ (L),0.1366\pm 0.0012\ (M),0.1026\pm 0.0096\ (H),' \end{array}$	
Chemical liver injury	Water	Animal: C57BL/6 male mice at 8–10 weeks of age Cell: BRL-3A and AML12 Model: Induction of APAP (300 mg/kg, 40 mM) Treatment: Water extract (0.3 mg/kg, 3 g/kg) in mice for 2 weeks; Water extract (100–400 μg/ mL) in BRL-3A for 24 h. Water extract (100–400 μg/mL) in AML12 for 8 h	ALT↓, AST↓, ROS↓, TNF-α↓, 1L-1β↓, HO-1↓, NQO1↓, Cell viability↑, GSH↑	Li J. et al. (2023)
Drug-induced liver injury	Ethanol	Animal: C57BL/6 (male); Cell: BRL-3A Model: Induction of APAP (Cell: 40 mM, 8 h; Mice: 200 mg/kg); Treatment: ethanol extract (6.25, 12.5, 25 μg/mL) in BRL-3A; ethanol extract (0.3, 1, 3 g/kg) in mice for 15 days	ALT↓, AST↓, ROS↓, MDA↓, Bax↓, Caspase3↓, Cleaved Caspase3↓, HO-1↑, NQO1↑, Cell viability↑, GSH↑	Liao (2023)
Liver protection	Petroleum ether	Animal: Sprague-Dawley rats (male) Model: Induction of ANIT (60 mg/kg) Treatment: Petroleum ether extract of 350 (L), 700 (M), 1400 mg/kg (H) for 5 days Positive control: Ursodeoxycholic acid (UDCA) (100 mg/kg) for 5 days	ALT J, AST J, ALP J, γ -GTP J, TBL J, DBL J, TBA J, degree of tissue damage J.(Compared with the model group) MDA/nmol ⁻ mg ⁻¹ : 1.24 ± 0.04, 4.02 ± 0.06, 3.91 ± 0.49 (L), 2.61 ± 0.32 (M), 1.84 ± 0.09 (H), 2.65 ± 0.28); MPO/U mg ⁻¹ : 3.70 ± 0.42, 24.10 ± 4.26, 23.44 ± 3.01 (L), 19.79 ± 1.74 (M), 12.13 ± 0.64 (H), 15.62 ± 0.75; NO/µmol ⁻¹ · 5.007 ± 2.678, 4.006 ± 0.732 (L), 3.523 ± 0.223 (M), 3.351 ± 0.194 (H), 2.678 ± 0.375; SOD/U mg ⁻¹ : 166.81 ± 10.80, (56.07 ± 4.62, 57.11 ± 4.19 (L), 62.56 ± 4.44 (M), 84.52 ± 7.02 (H), 109.02 ± 12.21; GST/ nmol ⁻¹ mg ⁻¹ ; 56.15 ± 6.39, 37.40 ± 2.85, 38.66 ± 3.92 (L), 43.75 ± 2.59 (M), 47.60 ± 1.66 (H), 47.93 ± 3.27; NO/: 1.884 ± 0.122, 5.007 ± 2.678, 4.006 ± 0.732 (L) 3.523 ± 0.223 (M), 3.351 ± 0.194(H), 2.678 ± 0.375	Cao et al. (2017)

TABLE 2 The hepatoprotective pharmacology of *H. pedunculosum* seeds.

Liver disease	Extract/ Compound	Animal/cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
Chemical liver injury	Total lignans	Animal: ICR mice (male) Model: Induction of CCl ₄ (0.1%, 20 mL/kg) Treatment: Total lignans (0.375, 0.75, 1.5, 3 g/kg) for 7 days Positive control: Compound glycyrrhizin tablets of 113 mg/kg (P1) and biphenyl diester of 200 mg/kg (P2) for 7 days	$ \begin{array}{l} {\rm ALT/UL}^{-1}\!\!: 50.68 \pm 3.66, 259.70 \pm 3.58, 231.81 \pm 16.73 \; (0.375\; g/kg)\; 210.71 \pm 9.08\; (0.75\; g/kg)\; 218.25 \pm 6.17\; (1.5\; g/kg)\; 202.86 \pm 11.80\; (3\; g/kg), \\ 194.85 \pm 17.46\; (P1)\; 220.29 \pm 7.77\; (P2);\; {\rm AST/UL}^{-1}\!\!: 97.83 \pm 8.04,\; 274.50 \pm 7.35,\; 240.38 \pm 12.23\; (0.375\; g/kg)\; 233.17 \pm 17.42\; (0.75\; g/kg)\; 226.55 \pm 16.93\; (1.5\; g/kg)\; 213.31 \pm 27.07\; (3\; g/kg),\; 209.38 \pm 11.61\; (P1)\; 232.90 \pm 11.61\; (P2);\; {\rm ALP/UL}^{-1}\!\!: 117.88 \pm 12.99,\; 195.67 \pm 16.08,\; 143.28 \pm 12.46\; (0.375\; g/kg)\; 134.61 \pm 10.53\; (0.75\; g/kg)\; 134.61 \pm 12.73\; (1.5\; g/kg)\; 124.14 \pm 14.72\; (3\; g/kg),\; 158.29 \pm 9.55\; (P1)\; 131.74 \pm 21.67\; (P2);\; {\rm MDA/}\; nmol^{-}mgprot^{-1}\!\!: 12.54 \pm 1.59,\; 35.32 \pm 2.54,\; 23.64 \pm 2.82\; (0.375\; g/kg)\; 16.03 \pm 2.76\; (3\; g/kg),\; 17.43 \pm 2.44\; (P1)\; 20.67 \pm 1.98\; (P2);\; {\rm SOD/}\; Umgprot^{-1}\!\!: 76.84 \pm 3.59,\; 43.39 \pm 1.72,\; 52.75 \pm 2.58\; (0.375\; g/kg)\; 54.58 \pm 3.24\; (0.75\; g/kg)\; 550.2 \pm 1.20\; (1.5\; g/kg)\; 54.58 \pm 3.24\; (0.75\; g/kg)\; 550.2 \pm 1.20\; (1.5\; g/kg)\; 54.58 \pm 3.24\; (0.75\; g/kg)\; 550.2 \pm 1.20\; (1.5\; g/kg)\; 54.58 \pm 3.54\; (3\; g/kg),\; 50.79 \pm 1.93\; (P1)\; 49.75 \pm 1.93\; (P2);\; {\rm SOD/}\; Umgprot^{-1}\!\!: 996.76 \pm 81.60\; , 534.00 \pm 50.58\; 873.88 \pm 96.38\; (0.375\; g/kg)\; 896.26 \pm 151.70\; (0.75\; g/kg)\; 924.47 \pm 125.97\; (1.5\; g/kg)\; 975.95 \pm 152.21\; (3\; g/kg),\; 751.57 \pm 46.27\; (P1)\; 796.84 \pm 83.47\; (P2) \end{array}$	Zhao et al. (2015)
Hepatic fibrosis	Total lignans	Animal: Sprague-Dawley rats (male) Model: Induction of CCl ₄ (40%, 25 mg/kg) Treatment: Total lignans of 100 (L), 200 (M), 400 mg/kg (H) for 8 weeks	$ \begin{array}{l} ALT/U'L^{-1}\!\!: 82.25 \pm 5.47, 200.00 \pm 22.60, 139.86 \pm \\ 21.05 (L) 106.63 \pm 16.60 (M) 92.75 \pm 18.42 (H), \\ 87.75 \pm 114.47; AST/U'L^{-1}\!: 169.25 \pm 13.96, \\ 217.57 \pm 33.76, 225.86 \pm 9.86 (L) 202.38 \pm 38.03 \\ (M) 178.00 \pm 31.96 (H), 185.50 \pm 30.87; ALP/ \\ U'L^{-1}\!\!: 158.00 \pm 4.04, 201.29 \pm 25.45, 151.14 \pm \\ 226.17 (L) 171.25 \pm 31.32 (M) 145.50 \pm 18.53 \\ (H), 136.50 \pm 28.4; TGF-\beta1/ngL^{-1}\!\!: 173.37 \pm 2.94, \\ 225.15 \pm 17.99, 210.64 \pm 11.67 (L) 196.79 \pm 15.77 \\ (M) 188.32 \pm 16.64 (H), 193.11 \pm 13.22; HA/ngL^{-1}\!\!: 248.21 \pm 9.99, 313.55 \pm 16.29, 291.63 \pm 11.37 \\ (L) 273.21 \pm 19.14 (M) 272.20 \pm 21.30 (H), \\ 271.04 \pm 10.42; HYP/\mugL^{-1}\!\!: 672.15 \pm 10.85, \\ 810.04 \pm 25.60, 791.46 \pm 21.34 (L) 742.96 \pm 27.21 \\ (M) 728.60 \pm 40.68 (H), 725.27 \pm 19.86; SOD/ \\ \mu gL^{-1}\!\!: 10.88 \pm 0.28, 9.04 \pm 0.46, 9.40 \pm 0.46 (L) \\ 10.02 \pm 0.44 (M) 10.23 \pm 0.67 (H), 10.23 \pm 0.39 \\ \end{array}$	Liu et al. (2017a)
Acute alcoholic liver injury	Total lignans	Animal: KM mice (male) Model: 56° Beijing Red Star Erguotou wine Treatment: Total lignans of 15 (L), 25 (M), 35 mg/kg (H) for 30 days Positive control: Polyene phosphatidylcholine (135 mg/kg) for 30 days	AST/UL ⁻¹ : 143.7 ± 12.0, 258.7 ± 28.3, 230.0 ± 23.3 (L) 200.2 ± 25.5 (M) 222.2 ± 28.2 (H), 185.8 ± 39.6; ALT/UL ⁻¹ : 56.5 ± 6.5, 155.0 ± 27.8, 1123.3 ± 26.1 (L) 92.8 ± 14.7 (M) 98.5 ± 15.3 (H), 99.8 ± 9.6; MDA/[nmol(mgpro) ⁻¹]: 1.07 ± 0.14, 1.99 ± 0.87, 1.69 ± 1.26 (L) 1.14 ± 0.27 (M) 1.21 ± 0.28 (H), 1.22 ± 0.15; XOD/[U(mg pro) ⁻¹]: 13.7 ± 1.3, 5.3 ± 3.1, 6.5 ± 1.2 (L) 8.6 ± 1.7 (M) 7.4 ± 1.0 (H), 9.9 ± 22.9; Na ⁺ -K ⁺ -ATP/ [µmolPi(mgproh) ⁻¹]: 0.98 ± 0.14, 0.38 ± 0.06, 0.63 ± 0.18 (L) 0.76 ± 0.08 (M) 0.82 ± 0.10 (H), 0.75 ± 0.07; SOD/[U(mgpro) ⁻¹]: 65.8 ± 5.1, 61.2 ± 2.8; (L) 62.7 ± 5.7 (M) 60.0 ± 4.3 (H), 59.6 ± 2.8; GSH-Px/[U(mgpro) ⁻¹]: 21.1 ± 7.9, 9.5 ± 2.5, 14.3 ± 1.2 (L) 12.2 ± 1.7 (M) 13.4 ± 0.7 (H), 13.7 ± 1.0	Huang et al. (2017)
Chronic alcoholic liver injury		Animal: Wistar rats (male) Model: 56° liquor (8 mL/kg-15 mL/kg) for 8 weeks Treatment: Total lignans of 100 (L), 200 (M), 400 mg/kg (H) for 8 weeks Positive control: Yishanfu (95 mg/kg) for 8 weeks	$ \begin{array}{l} {\rm AST/UL}^{-1}\!$	Huang et al. (2018)

TABLE 2 (Continued) The hepatoprotective pharmacology of H. pedunculosum seeds.

Liver disease	Extract/ Compound	Animal/cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
			$\begin{array}{l} 1.32 \pm 0.31; \ ADH/[nmol/(min'mg pro)]: \ 3.83 \pm 0.82, 12.38 \pm 3.60, 7.75 \pm 2.89 (L) 5.99 \pm 1.77 (M) \\ 6.91 \pm 1.42 (H), \ 8.39 \pm 44.43; \ TG/mmol·L^{-1}: \\ 7.63 \pm 0.73, \ 10.62 \pm 0.74, \ 9.55 \pm 0.99 (L) \ 8.51 \pm 0.67 (M) \ 8.75 \pm 0.63 (H), \ 8.01 \pm 1.67; \ SOD/ \\ [U'(mg prot)^{-1}]: \ 423.81 \pm 75.64, \ 193.52 \pm 40.85, \\ 317.09 \pm 52.41 (L) \ 233.66 \pm 64.95 (M) \ 296.12 \pm 34.64 (H), \ 196.23 \pm 80.47; \ GSH/[mg (g prot)^{-1}]: \\ 4.47 \pm 1.81, \ 1.47 \pm 0.47, \ 2.77 \pm 0.39 (L) \ 3.60 \pm 0.33 (M) \ 2.93 \pm 0.53 (H), \ 2.11 \pm 1.04; \ GSH-Px/ \\ [U'(mg prot)^{-1}]: \ 40.2 \pm 4.45, \ 34.1 \pm 3.85, \ 39.1 \pm 4.85 (L) \ 39.5 \pm 3.25 (M) \ 35 \pm 2.71 (H), \ 41.5 \pm 4.23; \ CAT/UmL^{-1}: \ 10.03 \pm 1.13, \ 7.09 \pm 1.26, \\ 9.08 \pm 0.51 (L) \ 9.17 \pm 1.18 (M) \ 8.31 \pm 0.95 (H), \\ 9.36 \pm 0.93; \ ALDH2/[nmol/(min'mg pro)]: \\ 9.62 \pm 1.96, \ 3.40 \pm 1.33, \ 4.96 \pm 1.59 (L) \ 5.78 \pm 3.53 (M) \ 3.07 \pm 1.37 (H), \ 5.83 \pm 3.78 \end{array}$	
Cholestatic liver injury		Animal: KM mice (male) Model: Induction of ANIT (0.4%, 80 mg/kg) Treatment: Total lignans (0.05, 0.1, 0.2, 0.4 g/kg) for 7 days Positive control: Bifendate Pills group (0.15 g/kg) for 7 days	AST/UL ⁻¹ : 36.81 ± 11.13, 197.99 ± 11.67, 173 ± 21.48 (0.05 g/kg) 127.02 ± 11.07 (0.1 g/kg) 120.56 ± 16.87 (0.2 g/kg) 107.67 ± 44.34 (0.4 g/kg), 156.83 ± 16.49; ALT/UL ⁻¹ : 26.87 ± 14.69, 470.15 ± 18.68, 275.82 ± 17.69 (0.05 g/kg) 223.29 ± 42.17 (0.1 g/kg) 206.47 ± 25.35 (0.2 g/kg) 384.08 ± 26.11 (0.4 g/kg), 220.50 ± 46.87; ALP/U ⁻¹ : 3.4 ± 0.6, 18.27 ± 2.53, 13.40 ± 1.87 (0.05 g/kg) 11.89 ± 3.12 (0.1 g/kg) 9.88 ± 2.04 (0.2 g/kg) 11.91 ± 1.36 (0.4 g/kg), 8.26 ± 2.23; TBA/µmolL ⁻¹ : 3.63 ± 0.35, 78.10 ± 8.38, 48.13 ± 8.98 (0.05 g/kg) 44.13 ± 13.28 (0.1 g/kg) 31.83 ± 5.84 (0.2 g/kg) 50.57 ± 17.10 (0.4 g/kg), 26.94 ± 110.15; TBIL/µmolL ⁻¹ : 1.62 ± 0.66, 191.57 ± 34.47, 106.56 ± 22.48 (0.05 g/kg) 44.65 ± DBIL/µmolL ⁻¹ : 0.87 ± 0.19, 122.98.9 ± 17.11 (0.2 g/kg) 96.07 ± 18.03 (0.4 g/kg), 41.96 ± 24.65; DBIL/µmolL ⁻¹ : 0.87 ± 0.19, 124.94 ± 18.72, 27.23 ± 9.13 (0.05 g/kg) 16.76 ± 10.48 (0.1 g/kg) 10.91 ± 6.21 (0.2 g/kg) 8.02 ± 2.18 (0.1 g/kg) 312.37 ± 15.70 (0.4 g/kg), 368.28 ± 15.36); MDA/molrg ⁻¹ : 2.41 ± 0.92, 12.66 ± 1.61, 6.91 ± 0.95 (0.05 g/kg) 18.77 ± 3.78 (0.4 g/kg), 15.3 ± 4.83 (0.2 g/kg) 18.77 ± 3.78 (0.4 g/kg), 19.41 ± 3.14; GSH-Px/mgg ⁻¹ : 132.54 ± 24.50, 21.51 ± 8.74, 54.45 ± 14.00 (0.05 g/kg) 77.88 ± 10.77 (0.4 g/kg), 89.81 ± 30.43; TNF-α/ngL ⁻¹ : 43.63 ± 2.07, 65.14 ± 7.40, 52.38 ± 3.34 (0.02 g/kg) 48.21 ± 0.95 (0.5 g/kg) 18.77 ± 3.78 (0.4 g/kg), 19.41 ± 3.14; GSH-Px/mgg ⁻¹ : 132.54 ± 24.50, 21.51 ± 8.74, 54.45 ± 14.00 (0.05 g/kg) 17.08 ± 9.17 (0.1 g/kg) 8.91 ± 0.01 g/kg) 45.81 ± 2.09 (0.2 g/kg) 46.75 ± 3.10 (0.4 g/kg), 44.22 ± 2.5; MCP-1/ngL ⁻¹ : 31.11 ± 2.34, 226.06 ± 43.42, 155.01 ± 30.14 (0.05 g/kg) 117.14 ± 24.86 (0.1 g/kg) 110.79 ± 19.70 (0.2 g/kg) 154.40 ± 36.39 (0.4 g/kg), 129.28 ± 32.20	Li et al. N. J. (2023)
acute alcoholic liver injury	Total sterols	Animal: ICR mice (male) Model: Induction of CCl ₄ (0.3%, 10 mL/kg) Treatment: Total sterols extract(10, 20, 50 mg/kg) for 7 days Positive control: Silymarin (50 mg/kg) for 7 days	AST↓, ALT↓, IL-1β↓, IL-6↓, COX-2↓, IL-10↑	Liu et al. (2022)

TABLE 2 (Continued) The hepatoprotective pharmacology of H. pedunculosum seeds.

Liver disease	Extract/ Compound	Animal/cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
Immunological liver injury	Fatty acid	Animal: Swiss mice Model: 2.5 mg BCG was given by tail injection Treatment: Fatty acid extract of 7 (L), 10 (M), 14.5 mL/kg (H) for 12 days Positive control: Bifendate (200 mg/kg) for 12 days	$ \begin{array}{l} MDA/nmol mg^{-1} : 16.26 \pm 4.29, \ 20.56 \pm 3.61, \\ 16.51 \pm 2.89 \ (L) \ 19.36 \pm 3.01 \ (M) \ 19.29 \pm 1.99 \\ (H), \ 17.73 \pm 1.01; \ ALT/UL^{-1} : 7.67 \pm 1.27, \ 90.71 \pm \\ 16.62, \ 23.32 \pm 8.30 \ (L) \ 45.83 \pm 16.92 \ (M) \ 29.16 \pm \\ 16.90 \ (H), \ 18.84 \pm 8.73; \ AST/UL^{-1} : 23.48 \pm 4.39, \\ 92.39 \pm 10.81, \ 47.61 \pm 5.37 \ (L) \ 51.54 \pm 13.11 \ (M) \\ 44.72 \pm 15.61 \ (H), \ 54.44 \pm 17.37; \ NO/\mumol L^{-1} : \\ 3.33 \pm 1.69, \ 21.26 \pm 8.20, \ 8.45 \pm 2.13 \ (L) \ 14.21 \pm \\ 9.43 \ (M) \ 10.77 \pm 3.70 \ (H), \ 7.38 \pm 4.66; \ SOD/ \\ Umg^{-1} : 184.40 \pm 17.25, \ 105.00 \pm 22.71, \ 219.95 \pm \\ 16.13 \ (L) \ 196.19 \pm 23.09 \ (M) \ 228.28 \pm 27.69 \ (H), \\ 127.89 \pm 12.69 \end{array} $	Chen et al. (2014)
Liver protection		Animal: Sprague-Dawley rats (male) Model: Induction of CCl ₄ (3 mL/kg) Treatment: Fatty acid extract of 1(L), 2 (M), 4 g/kg (H) for 5 days Positive control: Bifendate (200 mg/kg) for 5 days	$\begin{split} & TG/nmol{L^{-1}:} 0.67 \pm 0.21, 2.18 \pm 0.53, 1.10 \pm 0.38 \\ & (L) \ 1.03 \pm 0.40 \ (M) \ 0.82 \pm 0.1 \ (H), \ 1.44 \pm 0.34; \\ & HDL/nmol{L^{-1}:} 0.99 \pm 0.19, \ 1.30 \pm 0.11, \ 0.43 \pm \\ & 0.32 \ (L) \ 0.50 \pm 0.13 \ M) \ 0.59 \pm 0.12 \ (H), \ 0.57 \pm \\ & 0.11; \ LDL/nmol{L^{-1}:} 1.03 \pm 0.24, \ 1.65 \pm 0.10, \\ & 1.11 \pm 0.37 \ (L) \ 1.08 \pm 0.33 \ (M) \ 1.14 \pm 0.20 \ (H), \\ & 1.06 \pm 0.19; \ MDA/[nmol (mg prot^{-1})]: \ 1.30 \pm \\ & 0.11, \ 0.43 \pm 0.32 \ (L) \ 0.50 \pm 0.13 \ (M) \ 0.59 \pm 0.12 \\ & (H), \ 0.57 \pm 0.11; \ SOD/UL^{-1}: \ 57.69 \pm 15.08, \\ & 42.86 \pm 10.76, \ 74.28 \pm 17.91 \ (L) \ 97.30 \pm 12.51 \\ & (M) \ 102.69 \pm 29.39 \ (H), \ 100.57 \pm 21.66; \ TBIL/ \\ & Umol{L^{-1}:} \ 1.15 \pm 0.98, \ 11.89 \pm 3.87, \ 6.54 \pm 1.58 \\ & (L) \ 5.67 \pm 2.07 \ (M) \ 4.75 \pm 1.09 \ (H), \ 9.7 \pm 2.6; \\ & AST/UL^{-1}: \ 22.00 \pm 35.03, \ 1084.86 \pm 289.13, \\ & 1181.38 \pm 178.33 \ (L) \ 1039.43 \pm 244.18 \ (M) \\ & 310.10 \pm 33.99 \ (H), \ 1394.20 \pm 278.11; \ ALP/UL^{-1}: \ 136.7 \pm 23.3, \\ & 281.6 \pm 36.30, \ 220.8 \pm 34.3 \ (L) \ 185.0 \pm 21.3 \ (M) \\ & 141.3 \pm 27.8 \ (H), \ 191.4 \pm 29.4 \end{split}$	Li et al. (2014)
Immunological liver injury	Polysaccharide	Animal: KM mice (male) Model: ConA (30 mg/kg) injection into the tail vein Treatment: Polysaccharide of 0.71 (L), 0.99 (M), 1.44 g/kg (H) for 8 days Positive control: Bifendate (0.2 g/kg) for 8 days	ALT/U'L ⁻¹ : 9.0 ± 0.8, 143.6 ± 7.0, 130.2 ± 6.2(L) 115.9 ± 9.4 (M) 45.8 ± 4.7 (H), 42.6 ± 6.0; AST/ U'L ⁻¹ : 24.6 ± 2.4, 172.3 ± 9.4, 146.2 ± 15.4 (L) 124.2 ± 8.0 (M) 55.9 ± 4.4 (H), 172.3 ± 9.4; LDH/ U'L ⁻¹ : 1952.7 ± 133.7, 4606.6 ± 191.6, 3,948.3 ± 232.1 (L) 3,814.3 ± 227.8 (M) 3,187.9 ± 192.9 (H), 2,742.9 ± 179.3; NO/µmol'L ⁻¹ : 2.3 ± 0.2, 6.7 ± 0.5, 4.5 ± 0.3 (L) 4.1 ± 0.5 (M) 3.6 ± 0.4 (H) 3.4 ± 0.2; IL-6/pgmL ⁻¹ : 30.4 ± 1.1, 74.5 ± 2.1, 56.5 ± 3.7 (L) 50.1 ± 2.8 (M) 45.7 ± 2.9 (H), 51.4 ± 3.2; MDA/[(nmol/mgprot)]: 6.5 ± 0.3, 9.3 ± 0.5, 11.2 ± 0.7 (L) 9.0 ± 0.4 (M) 6.4 ± 0.7 (H), 7.5 ± 0.3; SOD/[(U/mgprot)]: 187.6 ± 4.4 59.7 ± 4.3, 74.6 ± 3.1 (L) 99.9 ± 7.0 (M) 126 ± 10.7 (H), 90.9 ± 10.0; Degree of tissue damage]	Li et al. (2015a)
Acute alcoholic liver injury	Herpetfluorenone	Animal: C57BL/6 mice; Cell: BMSCs Model: Induction of CCl ₄ Treatment: 100 μM of Herpetfluorenone	AST↓, ALT↓, ALP↓, TBA↓, MDA↓, ALB↑, SOD↑, GSH↑	Yang et al. (2023)
Acute alcoholic liver injury	Herpetin	Animal: C57BL/6 mice (male)Cell: BMSCs; Model: Induction of CCl ₄ Treatment: 10 μM of Herpetin	AST↓, ALT↓, AKP↓, ALB↑	Ding et al. (2023)
Immunological liver injury	Herpetin	Animal: ICR mice (male); Model: ConA (20 mg/kg) injection into the tail vein; Treatment: 10 (L), 20 mg/kg (H) of herpetin for 7 days Positive control: Qingkailing injection (20 mg/kg) for 5 days	$ \begin{split} & iNOS: 0.215 \pm 0.004, 0.290 \pm 0.013, 0.275 \pm 0.012 \\ & (L) \ 0.239 \pm 0.009 \ (H), \ 0.237 \pm 0.008; \ TNF-\alpha; \\ & 0.130 \pm 0.006, \ 0.166 \pm 0.008, \ 0.145 \pm 0.004 \ (L) \\ & 0.139 \pm 0.005 \ (H), \ 0.141 \pm 0.005; \ NF-\kappa B: \ 0.129 \pm 0.006, \ 0.150 \pm 0.004, \ 0.153 \pm 0.006 \ (L) \ 0.130 \pm 0.002 \ (H), \ 0.141 \pm 0.003; \ IFN-\gamma; \ 0.131 \pm 0.006, \\ & 0.149 \pm 0.006, \ 0.134 \pm 0.003 \ (L) \ 0.132 \pm 0.003 \\ & (H), \ 0.132 \pm 0.005; \ IL-4: \ 0.104 \pm 0.002, \ 0.129 \pm 0.004, \ 0.121 \pm 0.004 \ (L) \ 0.118 \pm 0.002 \ (H) \ 0.117 \pm 0.003; \ SOCS1: \ 0.120 \pm 0.007, \ 0.081 \pm 0.005, \\ & 0.087 \pm 0.007 \ (L) \ 0.091 \pm 0.008 \ (H), \ 0.105 \pm 0.011 \end{split} $	Wang et al. (2016)

Liver disease	Extract/ Compound	Animal/cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
Immunological liver injury	Herpetin	Animal: ICR mice (male) Model: Induction of BCG (2.5 mg) +LPS (7.5 μg) Treatment: 10 (L), 20 mg/kg (H) of herpetin for 12 days Positive control: Qingkailing injection (20 mg/kg) for 12 days	$ \begin{array}{l} {\rm AST/U:L^{-1}:96.01 \pm 9.40, 197.55 \pm 8.1, 184.33 \pm 15.86 \ (L) \ 161.59 \pm 18.20 \ (H), \ 123.55 \pm 11.07; \\ {\rm ALT/U:L^{-1}: 42.24 \pm 1.52, \ 101.61 \pm 5.05, 92.69 \pm 2.75 \ (L), \ 68.35 \pm 0.94 \ (M), \ 58.32 \pm 2.44; \ LDH/ \\ {\rm U:L^{-1}: 239.11 \pm 20.05, \ 546.87 \pm 18.16, \ 481.84 \pm 9.04 \ (L) \ 393.70 \pm 32.96 \ (H), \ 340.78 \pm 16.13; \\ {\rm MDA/nmolmg prot^{-1}: 15.98 \pm 1.39, \ 38.41 \pm 1.59, \ 35.61 \pm 1.87 \ (L) \ 29.6 \pm 1.52 \ (H), \ 24.38 \pm 2.03; \\ {\rm SOD/U'(mg prot^{-1}: 97.47 \pm 9.15, \ 68.08 \pm 12.80, \ 75.75 \pm 9.09 \ (L) \ 85.04 \pm 8.75 \ (H), \ 88.64 \pm 11.92; \\ {\rm GSH-Px/Umg prot^{-1}: 54.37 \pm 54.86, \ 292.78 \pm 57.38, \ 380.12 \pm 33.94 \ (L) \ 414.53 \pm 48.03 \ (H), \ 463.56 \pm 32.30 \end{array} $	Liu (2017b)

TABLE 2 (Continued) The hepatoprotective pharmacology of H. pedunculosum seeds.

(Dobrzyńska and Przysławski, 2020). Therefore, it is essential to study the fatty acids in *H. pedunculosum* seeds.

4.3 Terpenoids

Ten terpenoids (92-101, Figure 5) were identified in *H. pedunculosum* seeds, and triterpenoid was the dominant type among them. Triterpenoids have the activities of antiinflammatory, antibacterial, and antiviral properties (Xiao et al., 2018). For example, cucurbitacin B (95) was reported to show antiinflammatory, antioxidant, and neuroprotective effects (Dai et al., 2023). These bioactive triterpenoids in *H. pedunculosum* seeds doubtlessly contribute to its favorable pharmacologic actions.

4.4 Coumarins

Coumarin is widely acknowledged to have extensive biological activities including anti-tumor, anti-oxidation, anti-inflammation, and anti-coagulation (Kirsch et al., 2016; Wu et al., 2020). And there are 7 coumarins (102-108 in Figure 5) found in *H. pedunculosum* seeds up to now. For example, Huang et al. (2021) found that herpetolide H (107) from *H. pedunculosum* seeds had the effects of anti-inflammatory *in vitro*.

4.5 Others

In addition to the aforementioned metabolites, H. pedunculosum seeds also contain amino acids (109-114), flavonoids (115, 116), sterols (117-119), glucosides (120), esters (121, 122), olefin (123-124), and ketones (125) as illustrated in Figure 6. It is reported that leucine (112) and isoleucine (113) can prevent the fat accumulation from in hepatocyte (Zhang et al., 2022). Kaempferitrin (115) has anti-inflammatory and anti-oxidation effects (Patel D. K., 2021). The biological activity of stigmasterol (117) is found to include anti-inflammatory, antioxidant, and anticancer properties (Bakrim et al., 2022). Therefore, the role of these metabolites in the application of H. pedunculosum seeds deserves further research.

5 Pharmacology

Diverse studies have demonstrated the hepatoprotective, antioxidant, and anti-cholestasis effects of *H. pedunculosum* seeds and aforementioned metabolites. Especially, the action mechanism on liver protection effect of *H. pedunculosum* seeds was systematically generalized. The specific hepatoprotective action and other pharmacological effects were summarized in Table 2 and Table 3, respectively.

5.1 Hepatoprotective effect

Liver is a vital metabolic organ implementing multiple functions such as toxicant detoxification, protein synthesis, and special compound production, thus the increasing prevalence of liver illnesses including fatty liver, liver damage, fibrosis, cirrhosis, and cancer aroused great attention nowadays (Asrani et al., 2019). As collected in Table 2, plentiful researches showed the remarkable hepatoprotective effect of H. pedunculosum seeds through the adjustment of some enzymes in animal models with the induction of CCl₄, paracetamol (APAP), concanavalin A (ConA), α-naphthyl isothiocyanate (ANIT), liquor, bacillus calmette-guérin (BCG) and lipopolysaccharides (LPS). For instance, the ethyl acetate extract of H. pedunculosum seeds (EAEHPS) showed hepatoprotective activity against CCl₄-induced hepatic fibrosis in rats via the inflammatory pathway with obviously inhibiting the expression of NF-κB (IκBα), Samd3, and TGF-β1 proteins (Feng et al., 2018a). The water extract of H. pedunculosum seeds could alleviate APAP-induced liver injury by inhibiting oxidative stress and ferroptosis through activating the Nrf2 signal pathway (Li N. Z. et al., 2023). In addition, some proteins, such as NLRP3, TLR-2, TLR-4, and JNK, will have their expression reduced by the total lignan of H. pedunculosum seeds (TLHPS), so as to protect mice against ANIT-induced liver damage (Li J. et al., 2023). Some metabolites such as herpetfluorenone (HPF, 23) and herpetin (18) from H. pedunculosum seeds were further found to have a positive pharmaceutical effect on acute liver injury by promoting the differentiation of bone marrow mesenchymal stem cells into hepatocellular-like cells and controlling autoimmune oxidation (Yang et al., 2023; Ding et al., 2023).

Effects	Extract/ Compound	Animal/Cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
Antioxidation	Chloroform	Animal: SD rats Model: Induction of CCl ₄ (50%, 0.6 mg/kg) Treatment: chloroform extract of 200 (L), 400 mg/kg (H) for 7 days. Water extract of 200 (L), 400 mg/kg (H) for 7 days Positive control: VitE (400 mg/kg) for 7 days	$ \begin{array}{l} MDA/nmol^{-1} \ protein: \ 8.65 \pm 2.89, \ 16.92 \pm 4.75, \\ 7.22 \pm 1.94 \ (L) \ 7.34 \pm 0.97 \ (H), \ 5.16 \pm 0.64; \ SOD/ \\ unit mg^{-1} \ protein: \ 316.68 \pm 19.05, \ 237.62 \pm 17.81, \\ 292.83 \pm 41.64 \ (L) \ 289.52 \pm 40.07 \ (H), \ 289.00 \pm 25.29; \\ GSH-px/unit mg^{-1} \ protein: \ 146.36 \pm 24.67, \ 101.82 \pm \\ 24.17, \ 118.51 \pm 18.36 \ (L) \ 121.68 \pm 223.16 \ (H), \ 142.56 \pm \\ 16.61 \end{array} $	Fang et al. (2008)
	Water		$ \begin{array}{l} MDA/nmol-1mg^{-1} \ protein: 8.65 \pm 2.89, \ 6.89 \pm 1.26 \ (L) \\ 6.11 \pm 0.48 \ (H), \ 5.16 \pm 0.64 \ SOD/unit-1mg^{-1} \ protein: \\ 316.68 \pm 19.05, \ 272.29 \pm 25.97 \ (L) \ 308.15 \pm 13.34 \ (H), \\ 289.00 \pm 25.29; \ GSH-px/unit-1 \ protein: 146.36 \pm \\ 24.67, \ 142.48 \pm 10.83 \ (L) \ 148.25 \pm 12.35 \ (H), \ 142.56 \pm \\ 16.61 \end{array} $	-
Anti-fatigue	Chloroform	Animal: KM mice (the mice that could learn to swim, male) Treatment: chloroform extract of 80 (L), 160 (M), 320 mg/kg (H); Ethyl acetate extract of 80 (L), 160 (M), 320 mg/kg (H); n-Butanol extract of 80 (L), 160 (M) 320 mg/kg (H) for 30 days; herpetrione of 15 (L), 30 (M), 60 mg/kg(H) for 30 days	Swimming time \uparrow , survival time \uparrow ; HG/mgg ⁻¹ :9.99 ± 1.58,/, 10.40 ± 1.47 (L) 10.53 ± 1.56 (M) 10.58 ± 1.97 (H),/; LDH/U'L ⁻¹ : 874.50 ± 64.22,/, 900.56 ± 143.87 (L) 942.11 ± 127.10 (M) 961.84 ± 70.95 (H),/; SOD/U'mL ⁻¹ : 69.52 ± 9.79,/, 119.84 ± 16.13 (L) 118.50 ± 9.52 (M) 121.28 ± 8.44 (H),/; GSH-Px/U'L ⁻¹ : 109.56/, 119.84 ± 16.13 (L) 118.50 ± 9.52 (M) 121.28 ± 8.44 (H),/; BLA/ng 100mL ⁻¹ : 24.49 ± 1.99,/, 23.91 ± 2.85 (L) 23.19 ± 1.84 (M) 23.37 ± 1.67 (H),/; MDA/nmol'L ⁻¹ :14.04 ± 2.07,/, 13.92 ± 1.58 (L) 13.56 ± 1.91 (M) 13.43 ± 1.42 (H),/	Jin et al. (2016)
	Ethyl acetate		Swimming time [↑] , survival time [↑] ; HG/mgg ⁻¹ : 9.99 ± 1.58,/, 10.55 ± 1.60 (L) 10.90 ± 1.58 (M) 11.56 ± 1.28 (H),/; LDH/U·L ⁻¹ : 874.50 ± 64.22,/, 916.63 ± 137.80 (L) 996.50 ± 112.53 (M) 1073.66 ± 140.79 (H),/; SOD/U·m·L ⁻¹ : 69.52 ± 9.79,/, 118.69 ± 9.38 (L) 120.54 ± 11.04 (M) 123.78 ± 8.18 (H),/; GSH-Px/U·L ⁻¹ : 109.56 ± 9.58,/, 118.69 ± 9.38 (L) 120.54 ± 11.04 (M) 123.78 ± 8.18 (H) 1,/; BLA/ng100m·L ⁻¹ : 24.49 ± 1.99,/, 23.09 ± 1.70 (L) 22.16 ± 2.16 (M) 21.94 ± 2.24 (H),/; MDA/nmol·L ⁻¹ : 14.04 ± 2.07,/, 13.26 ± 1.47 (L) 12.261 ± 1.13 (M) 11.77 ± 1.44 (H),/	
	n-Butanol		$ \begin{array}{l} HG/mgg^{-1}: 9.99 \pm 1.58, /, \ 10.04 \pm 1.44 \ (L) \ 10.40 \pm 1.79 \\ (M) \ 11.45 \pm 1.14 \ (H), /; \ LDH/U:L^{-1}: 874.50 \pm 64.22, /, \\ 914.42 \pm 153.03 \ (L) \ 926.89 \pm 111.32 \ (M) \ 1028.14 \pm \\ 104.08 \ (H), /; \ SOD/U:mL^{-1}: 69.52 \pm 9.79, /, \ 117.02 \pm 17.47 \\ (L) \ 120.28 \pm 17.46 \ (M) \ 119.15 \pm 8.56 \ (H), /; \ GSH-Px/ \\ U:L^{-1}, /, \ 117.02 \pm 17.47 \ (L) \ 120.28 \pm 17.46 \ (M) \ 119.15 \pm \\ 8.56 \ (H), /; \ BLA/ng \ 100mL^{-1}: 24.49 \pm 1.99, /, \ 25.41 \pm 2.18 \\ (L) \ 24.54 \pm 2.64 \ (M)23.44 \pm 2.56 \ (H), /; \ MDA/nmol L^{-1}: \\ 14.04 \pm 2.07, /, \ 13.63 \pm 2.11 \ (L) \ 13.27 \pm 1.70 \ (M) \ 13.09 \pm \\ 1.21 \ (H), / \end{array} $	-
	herpetrione		Swimming time [↑] , survival time [↑] ; HG/mgg ⁻¹ ; 9.99 ± 1.58,/, 10.87 ± 1.38(L) 11.67 ± 1.37 (M) 11.75 ± 1.25 (H),/; LDH/UL ⁻¹ :874.50 ± 64.22,/,1003.27 ± 92.20 (L) 1046.10 ± 109.91 (M) 1092.73 ± 109.60 (H),/; SOD/UrnL ⁻¹ : 69.52 ± 9.79,/, 115.18 ± 11.96 (L) 10,220.44 ± 8.07 (M) 123.04 ± 11.36 (H),/; GSH-Px/UL ⁻¹ : 109.56 ± 9.58, 109.56 ± 9.58, 115.18 ± 11.96 (L) 120.44 ± 8.07 (M) 123.04 ± 11.36 (H),/; BLA/ng100mL ⁻¹ : 24.49 ± 1.99,/, 22.40 ± 1.85 (L) 21.75 ± 1.78 (M) 20.91 ± 1.91 (H),/; MDA/nmol·L ⁻¹ : 14.04 ± 2.07/, 12.15 ± 1.14 (L) 11.65 ± 1.24 (M) 11.50 ± 1.21 (H),/	
Anti-tumor	Lignans	Cell: BEL-7402, BEL-7404, HCT	IC50: 1.45 μg/mL, 1.68 μg/mL, 2.36 μg/mL	Yuan (2006a)
Anti- hyperuricemia	Ethanol	Animal: KM mice (male); Model: Intraperitoneal injection of potassium oxonate emulsion (300 mg/kg).	UA,, XO(/)	Wang et al. (2022b)
Anti-gouty arthritis		Treatment: ethanol extract (100, 200, 400 mg/kg) for 10 days. Positive control: colchicine (0.3 mg/kg) for 10 days	Weight↑, Articular swelling↓, IL-1β↓, TNF-α↓, UA↓	Wang et al. (2022b)

TABLE 3 The other pharmacology effects of *Herpetospermum pedunculosum* seeds.

Effects	Extract/ Compound	Animal/Cell and intervention	Indicators and results (control, model, treatment, positive control groups)	Refs.
Anti-cholestasis	Ethyl acetate	Animal: SD rats (male); Model: Induction of ANIT (60 mg/kg); Treatment: Ethyl acetate extract (100, 200, 400 mg/kg) for 7 days Positive control: UDCA (100 mg/kg) for 7 days	ALT↓, AST↓, ALP↓, γ-GTP↓, TBIL↓, DBIL↓ TBA↓, GSH↓, SOD↓, GPx↓, CAT↓	Wei et al. (2020)
Anti-skin inflammation	Ethanol	Animal: BALB/c mice (female); Cell: HaCat Model: Mice induced by IMQ for 7 days; Hacat cell induced by IFN- γ (2 ng/mL) for 24 h Treatment: ethanol extract (0.125, 1.25 and 12.5 µg/g) in mice for 7 days. Ethanol extract (12.5 mg/mL) in HaCat cell	IFN-γ↓, TNF-α↓, IL-17A↓, ICAM-1↓, CXCL9↓	Zhong et al. (2023)
Anti-candida albicans	Herpetin, herpetrione	_	Minimal inhibitory concentration of 10.5 μ M and 9.2 μ M, respectively	Dai et al. (2019)

TABLE 3 (Continued) The other pharmacology effects of Herpetospermum pedunculosum seeds.



The mechanism of protective effect of *Herpetospermum pedunculosum* seeds on liver. (A) NF- κ B signaling pathway; (B) TGF- β signaling pathway; (C) Keap1-Nrf2 signaling pathway.

Based on above discussions and previous literatures, the hepatoprotective mechanism of *H. pedunculosum* seeds can be summarized into three pathways as illustrated in Figure 7. The first one is the inhibition of NF- κ B signaling pathway to alleviate the inflammation during liver diseases (Figure 7A). *Herpetospermum pedunculosum* seeds can inhibit the phosphorylation of I κ B through the inhibition of IKK, which in turn has anti-inflammatory and hepatoprotective effects (Li N. Z. et al., 2023). The second mechanism is inhibit the phosphorylation of Smad3, which in turn inhibits the expression of relevant genes after the complex enters the nucleus, thus playing a role in inhibiting liver fibrosis (Feng et al., 2018a). The third one is the promotion of Keap1-Nrf2 signaling pathway (Figure 7C).

Nrf2 plays a crucial role in cellular defense against oxidative stress. When activated by *H. pedunculosum* seeds, the stability of Nrf2 increases, leading to reduced degradation and subsequent activation of genes driven by the antioxidant response element (ARE), thereby exerting a protective effect against liver damage (Li N. Z. et al., 2023; Liao, 2023).

5.2 Antioxidation

Fang et al. (2007), Fang et al. (2008) demonstrated the antioxidant activities of $CHCl_3$, water and ethanol extracts of *H. pedunculosum* seeds to prevent lipid peroxidation brought on by CCl_4 *in vivo* experiments. Jiang et al. (2020) tested the significant

inhibitory activity of neocucurbitacin D (92) (IC50 = 15.27 \pm 0.29 μ M) and 23, 24-dihydrocucurbitacin B (97) (IC50 = 24.18 \pm 0.26 μ M) on XOD. Gong, (2013) showed that herpetone (7) has good DPPH free radical scavenging ability and antioxidant activity. Although many studies have shown that *H. pedunculosum* seeds has antioxidant effects, there are still some problems, such as the simplistic evaluation index and the unclear relationship between dose and activity.

5.3 Anti-cancer cells

The lignan of H. pedunculosum seeds demonstrated considerable in vitro inhibitory action against several cancer cells. The IC50 of lignans in H. pedunculosum seeds were 1.45 µg/mL, 1.68 µg/mL, and 2.36 µg/mL for human hepatocellular carcinoma cells (BEL-7402, BEL-7404), and HCT, respectively (Yuan, 2006a). Zhang et al. (2007) demonstrated the inhibitory effects of herpetolide A (102) and herpetolide B (116) on the growth of human promyelocytic leukemia cells (HL-60). The metabolites of H. pedunculosum seeds including including herpetosiol A (42), herpetosiol C (44), 7', 8'-didehydlroherpepetotriol (14), herpetetrol (2), herpepropenal (13), herpetrione (6) showed significant cytotoxicity on human gastric adenocarcinoma cells (SGC7901), human lung cancer cells (A549), human breast cancer cells (MDA-MB-231), and human hepatocellular carcinoma cells (HepG2) (Ma, 2020; Kong et al., 2023). However, these studies only perform a simple detection of IC 50 and cytotoxicity, and lack other powerful indicators to reflect the efficacy of the drug. In addition, it is worth noting that the anti-tumor effects are mainly tested at the cellular level, lacking in animal and mechanism investigations, which are noteworthy in further research.

5.4 Anticholestasis effects

EAEHPS exerted an anti-cholestatic effect with increasing bile flow in a dose-dependent manner, which promoted bile acid transport by activating the farnesoid X receptor (FXR) signaling pathway (Wei, 2020). Meanwhile, the EAEHPS activated the Keap1-Nrf2 pathway to alleviate oxidative stress and inhibit of NF- κ B/Are signaling pathway to inhibit inflammatory response, which could prevent and treat ANITinduced cholestasis in rats (Wei et al., 2020).

5.5 Other effects

Wang S. W. et al. (2022) found that EAEHPS also had antihyperuricemia and anti-gouty arthritis activities, through reducing serum uric acid (UA) levels, suppressing the production and releasing pertinent inflammatory components, and lessening inflammatory damage and pathological tissue necrosis. Jin et al. (2016) demonstrated the anti-fatigue effects of ethanol extract of *H. pedunculosum* seeds with longer swimming time and hypoxia tolerance of experimental mice than that of the control group. The ethanol extract further showed a therapeutic effect on skin inflammation caused by imiquimod (Zhong et al., 2023). Moreover, Dai et al. (2019) showed that herpetin (18) and herpetrione (6) had favorable anti-candida albicans effects with minimal inhibitory connection of 10.5 μ M and 9.2 μ M, respectively.

6 Structure-activity relationship of lignan

Considering the key role of lignans in H. pedunculosum seeds, their structure-activity relationship was summarized according to previous literatures. For benzofuran lignans (Figure 2), H-5 can improve its antiinflammatory capacity when it remains unchanged (Wang L. X. et al., 2022). The electron-withdrawing or electron-donor groups on the benzene ring of benzofuran lignans can decrease their antituberculosis activity (Xu Z. et al., 2019). The anti-tumor activity of tetrahydrofuran lignans with the 7-O-9' structure (Figure 2B.) can be increased by fixing the following sites: C-7' is carbonyl group, H-5/5'is not substituted, and C-4/4'is methoxy (Wang L. X. et al., 2022). The antioxidant capacity of furofuran lignans is reported to decrease with the number of substituted methoxy groups on their benzene ring (Wang L. X. et al., 2022). Meanwhile, the presence of methoxy benzene in furofuran lignans enhances its toxicity to tumor cells (Xu W. H. et al., 2019), which could provide a structure-activity basis for the anti-tumor effect of herpetrione (6, Figure 3) (Yuan, 2006a; Yuan et al., 2006b; Yuan et al., 2011). For dibenzylbutane lignans (Figure 2), stronger antiviral activity can be achieved when the hydrogens at C-4 and C-5 are substituted by hydroxyl and methoxy groups respectively, and that at C-3'/4'/5' are substituted by methoxy or hydroxyl groups (Xu et al., 2022). Therefore, the separation and structural modification of lignan compounds from H. pedunculosum seeds show great potential for the development of drug leads.

7 Pharmaceutical analysis

Herpetospermum pedunculosum seeds are only stipulated qualitatively in the Chinese Pharmacopoeia, and their quantitative provisions are still lacking. The existing regulations are not enough to accurately evaluate the quality of *H. pedunculosum* seeds. Therefore, this section briefly introduces the latest research on modern analytical methods to provide guidance for quality evaluation for *H. pedunculosum* seeds.

Lignans such as herpetrione (6), herpetotriol (12), herpetin (18), and herpetfluorenone (23) are considered to be typical metabolites of the genus Herpetospermum and also the main active metabolites of H. pedunculosum seeds, which undoubtedly have a direct effect on the quality research of *H. pedunculosum* seeds and are indispensable to be detected. Wang, (2014) used herpetotriol (12) as the chemical reference materials in TLC to compare H. pedunculosum seeds from different areas. Cong et al. (2008) detected seven lignans from different areas by reversed-phase HPLC method. The results showed that herpetrione (6) was the most abundant among the seven metabolites, followed by herpetotriol (12). Qian et al. (2011) further accurately analyzed the average content of herpetrione (6) in 10 batches of H. pedunculosum seeds from different areas by UPLC, which was found to be 3.7223 mg g⁻¹. Except lignan, other metabolites such as fatty acids and polysaccharides also contribute to the bioactivity of H. pedunculosum seeds, and their analysis are meaningful for the quality evaluation of H. pedunculosum seeds. Ling et al. (2018) detected four fatty acids in H. pedunculosum seeds by GC, the result showed that the content of oleic acid (82) was highest, followed by palmitic acid (81). Liu M. L., (2017a) combined UV-Vis and phenol-sulfuric acid methods to detect the polysaccharides in 10 batches of H. pedunculosum seeds, indicating higher polysaccharide

No	Name	Composition	Efficacy	Refs.
1	Sanwei Qiangwei powder	Rosa multiflora, Herpetospermum caudigerum, Terminalia chebula	Clear heat and remove toxins, promote bile flow, For the treatment of Tri-pa and gallbladder diseases	Chinese Pharmacopoeia Commission (1995)
2	Jiuwei Zhangyacai pill	Swertia bimaculata, Herpetospermum caudigerum, Aconitum tanguticum, Ixeris polycephala, Berberis kansuensis, Lagotis Gaertn, Hypecoum erectum, Radix Aucklandiae, Chrysosplenium sinicum	Clear heat, anti-inflammatory, alleviates pain. For cholecystitis and incipient icteric hepatitis	
3	Wuwei Jinse pill	Terminalia chebula, Herpetospermum caudigerum, semen punicae granati, faeces soris scrofae, Radix aucklandiae	Clear heat and promote bile flow, promote digestion. For the treatment of jaundice hepatitis, and gallbladder pain	
4	Shiwei gaining pill	Carthami flos, Crocus sativus, Herpetospermum caudigerum, Meconopsis integrifolia, Dracocephalum tanguticum, Saxifraga stolonifera, Corydalis impatiens, Bear gallbladder, Calculus bovis, Brag-zhun, Calciosinti, and Turquoisis	It is used to treat fatty liver, viral hepatitis, liver fibrosis, cirrhosis, and other liver injuries	Feng et al. (2018b)
5	Qiwei hezi powder	Terminalia chebula, Herpetospermum caudigerum, Bombax ceiba, Amomum tsaoko Crevost, Syzygium aromaticum, Nardostachys chinensis, Piper longum	Clear heat and relieve pain. It is used for spleen enlargement, pain and spleen heat caused by strain injury	Yuandan and Song (1987)
6	Songshi pill	Songshi, Borneol, Syzygium aromaticum, Santalum album, Pulvis fellis ursi, Forest musk abelmosk, Herpetospermum caudigerum	Clear heat and remove toxins, soothe liver. It is used to treat liver pain, cirrhosis, hepatitis and cholecystitis	Xu et al. (2023)
7	Shiwei heibingpian powder	Borneol, Pomegranate seed, Cinnamomum cassia, Myristica fragrans, Piper longum, Terminalia chebula, Light halititum, Herpetospermum caudigerum, Holarrhena antidysenteriaca, Pulvis fellis ursi	It is used to treat nausea, cholecystitis, gallstones, and jaundice	Cang and De (2020)

TABLE 4 Formulations and preparations of *H. pedunculosum* seeds.

content (2.16%) of *H. pedunculosum* seeds produced in Yunnan province. However, it is difficult to accurately evaluate the quality of *H. pedunculosum* seeds based on single or several metabolite analyses owing to its plentiful active metabolites, and establishing their fingerprint for similarity evaluation and principal component analysis could be a feasible choice in this aspect. Wang, (2014) found that there were 18 common peaks in the HPLC fingerprint, and the content of herpetolide A (102) was relatively high in all the samples to be analyzed. Subsequently, the HPLC fingerprint of *H. pedunculosum* seeds from Nyingchi region of Tibet was also studied, and 17 common peaks were identified, among which herpetrione (6) was the highest (Chen et al., 2020b).

In brief, among the active metabolites suitable for quantitative analysis, herpetrione (6) and herpetolide (102) exhibit various pharmacological activities with relatively high content, which have the potential to serve as markers for evaluating the quality of *H. pedunculosum* seeds. The current analysis methods for *H. pedunculosum* seeds are still far from perfect to establishing their quality evaluation system. It is urgent to elucidate the key indicative metabolites of *H. pedunculosum* seeds and develop standard determination methods capable of evaluating its quality comprehensively.

8 Processing

Processing methods are able to change the effect of *H. pedunculosum* seeds. For example, the stir-frying with grit can effectively alleviate the side effects of diarrhea caused by the shell

of *H. pedunculosum* seeds. Meanwhile, the content of herpetrione (6) significantly decreased by 40.9% during this process, which can affect the clinical efficacy (Ling et al., 2018). Research further revealed that *H. pedunculosum* seeds processed by stir-frying with vinegar has better effects on protecting the liver and reducing enzymes, compared with sand owing to the lower herpetrione loss (12%) than that stir-frying with sand (41.4%). (Chen et al., 2016). Additionally, preparing the lignans of *H. pedunculosum* seeds into nanosuspension can improve their bioavailability and stability (Li et al., 2018; Shen et al., 2016). Therefore, the processing optimization could be a feasible approach to enhance the efficacy of *H. pedunculosum* seeds, which deserves more detailed research.

9 Application

The commercial herbal formulae including *H. pedunculosum* seeds and related details were collected in Table 4. For example, *H. pedunculosum* seeds is often combined with *Swertia bimaculata*, *Terminalia schedule*, and *Carthami flos* (1, 2, 3 in Table 4) to soothe the liver, promote bile flow, clear heat, and detoxify. When it is paired with *Rosa multiflora*, *T. schedule*, *Phylanthus emblica* (1, 2, 3, 4 in Table 4), formed compound medicines have the effects of strengthening the spleen, as well as promoting digestion. These summarizations and analyses supported the clinical practice of *H. pedunculosum* seeds and provided reference value for the development of other *H. pedunculosum* seed-derived prescriptions.

10 Conclusions and prospects

Herpetospermum pedunculosum seeds is a traditional Tibetan medicine with long history, rich chemical metabolites and high medicinal value. The research of *H. pedunculosum* seeds has achieved fruitful results and provided a scientific basis for the clinical medication. However, there are some shortcomings that need to be addressed in follow-up studies.

Although H. pedunculosum seeds is present in many Chinese patent medicines for the treatment of liver diseases, the interaction between the chemical metabolites in the prescriptions remains unclear and needs further investigation. Secondly, the supply of H. pedunculosum seeds is restricted due to the particular growth environment and limited wild resources. The large-scale cultivation of H. pedunculosum seeds could be of high research and economy value. Herpetospermum pedunculosum seeds are reported to contain 125 chemical metabolites, and lignan, terpenoids and coumarin are the main metabolites. Among them, lignan has been widely studied, which is usually recognized as the main pharmacological metabolite of H. pedunculosum seeds to exert hepatoprotective effect. However, the research on many other potentially active components such as polysaccharide is still in shortage. More advanced technologies can be used to extract, enrich, separate and purify the metabolites with low content and attention for better understanding of the medicinal material base of H. pedunculosum seeds. Moreover, there is a lack of structure-activity relationship studies of other active mmetabolites except lignans in H. pedunculosum seeds. The systematic structureactivity relationship studies can accelerate the synthesis of active metabolites and the development of related drugs derived from H. pedunculosum seeds.

The pharmacological effects of *H. pedunculosum* seeds, especially its effects on liver diseases, have been extensively researched. However, there are few in-depth studies on other pharmacological effects, and the current pharmacological research only remains at the cell and animal levels without comprehensive clinical research. Future research should take this as the direction to accelerate the clinical translation of drugs. Moreover, the quality standard of *H. pedunculosum* seeds still lacks the indicative components and standard detection method, which can be disadvantageous for standard pharmacology research and clinic practice. At present, some analytical methods have been used to detect the main bioactive ingredients with relatively high content such as herpetrione (6) and herpetolide (102), which may be a promising direction for better quality evaluation.

Although the current medical use of *H. pedunculosum* seeds is without processing, some studies have shown that *H. pedunculosum* seeds stir-fried with sand and vinegar can reduce their side effect of diarrhea and also the content of active ingredients. Therefore, the effect of processing method needs to be systematically determinated and optimized in combination with pharmacology and clinical research. In summary, this paper has comprehensively reviewed

References

and analyzed the botany, phytochemistry, pharmacology, analytical methods and quality evaluation, processing and application of *H. pedunculosum* seeds, which can provide more insights for further research and development of traditional Tibetan medicine.

Author contributions

ZJ: Writing-original draft. CZ: Writing-original draft. XY: Writing-original draft. KW: Writing-original draft. ZS: Writing-original draft. WG: Writing-original draft. QaZ: Writing-original draft. XM: Formal analysis, Funding acquisition, Writing-review and editing. LQ: Writing-review and editing. QmZ: Writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Financial support from Zhejiang Provincial Natural Science Foundation of China (LY24H290005), National Natural Science Foundation of China (82004208), and Research Project of Zhejiang Chinese Medical University (2023GJYY16; GQD23SH23, BZXCG-2022-37).

Acknowledgments

It is also appreciated for the assistance from the Public Platform of Pharmaceutical Research Center, Academy of Chinese Medical Science, Zhejiang Chinese Medical University and Shiyanjia Lab (www.shiyanjia.com).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Asrani, S. K., Devarbhavi, H., Eaton, J., and Kamath, P. S. (2019). Burden of liver diseases in the world. J. Hepatol. 70 (1), 151-171. doi:10.1016/j.jhep.2018.09.014

Bakrim, S., Benkhaira, N., Bourais, I., Benali, T., Lee, L. H., El Omari, N., et al. (2022). Health benefits and pharmacological properties of stigmasterol. *Antioxidants (Basel.)* 11 (10), 1912. doi:10.3390/antiox11101912

Cang, J., and De, J. (2020). Clinical observation on the treatment of jaundice hepatitis with Tibetan medicine Shiwei heibing tables. J. Med. Pharm. Chin. Minor. 26, 3–5. doi:10.16041/j.cnki.cn15-1175.2020.05.002

Cao, W. R., Ge, J. Q., Xie, X., Fan, M. L., Fan, X. D., Wang, H., et al. (2017). Protective effects of petroleum ether extracts of Herpetospermum caudigerum against α -

naphthylisothiocyanate-induced acute cholestasis of rats. J. Ethnopharmacol. 198, 139–147. doi:10.1016/j.jep.2017.01.003

Chen, H. G., Shen, B. D., Shen, C. Y., Li, Z. M., and Yuan, H. L. (2016). Effects of different processing technology on active ingredients diarrhea and hepatoprotection of *Herpetospermum caudigerum*. *Pharm. J. Chin. People's Lib. Army.* 32, 289–292+298.

Chen, J. F. (2020). Study on potential toxicity, antibacterial activity, and chemical constituents of the shell of Herpetospermum pedunculosum. Master. Jiangsu: Nanjing University of Science and Technolog.

Chen, L., Zhang, M., Yao, H. E., Li, C. Q., and He, C. Y. (2014). Protective effect of Herpetospermum seed oil on immunologic liver injury in the mice. *West China J. Pharm. Sci.* 29, 143–145.

Chen, X., Lu, X. G., Feng, X., and Zhong, G. J. (2020b). HPLC fingerprint of Tibetan medicine hertospermi semen from Linzhi Tibet. *Cent. South Pharm.* 18, 664–667.

Chinese Materia Medica Commission (1998). Chinese Materia Medica. Shanghai: Shanghai Science and Technology Press.

Chinese Pharmacopoeia Commission (1995). Pharmacopoeia of the people's Republic of China, Beijing: China. Med. Sci. Press.

Cong, L. B., Yuan, H. L., Wang, Q., Li, X. Y., Gong, Q. F., and Xiao, X. H. (2008). Simultaneous determination of seven bioactive lignans in *Herpetospermum caudigerum* by RP-HPLC method. *Biomed. Chromatogr. BMC* 22 (10), 1084–1090. doi:10.1002/ bmc.1028

Dai, S., Wang, C., Zhao, X. T., Ma, C., Fu, K., Liu, Y. F., et al. (2023). Cucurbitacin B: a review of its pharmacology, toxicity, and pharmacokinetics. *Pharmacol. Res.* 187, 106587. doi:10.1016/j.phrs.2022.106587

Dai, Y. X., Hu, S., Jiang, H. Z., and Tan, R. (2019). Study on phenolic constituents from *Herpetospermum caudigerum*. Nat. Prod. R&D. 31 (02), 280–283. doi:10.16333/j. 1001-6880.2019.2.016

Dai, Y. X., Wu, W. J., and Tan, R. (2017). Study on the chemical components of the ethyl acetate extract from *Herpetospermum caudigerum*. *North Am. J. Med. Sci.* 10 (04), 136–138.

Ding, Y., Tan, R., Gu, J., and Gong, P. Y. (2023). Herpetin promotes bone marrow mesenchymal stem cells to alleviate carbon tetrachloride-induced acute liver injury in mice. *Molecules* 28 (9), 3842. doi:10.3390/molecules28093842

Dobrzyńska, M. A., and Przysławski, J. (2020). The effect of camelina oil (α -linolenic acid) and canola oil (oleic acid) on lipid profile, blood pressure, and anthropometric parameters in postmenopausal women. *Arch. Med. Sci.* 17 (6), 1566–1574. doi:10.5114/ aoms.2020.94033

Dong, Z. Y., Wang, H., Ma, Y. X., Lan, X. Z., and Chen, M. (2019). Chemical constituents from *Herpetospermum caudigerum*. Chin. Tradit. Pat. Med. 41, 341–344.

Fan, X. D., Wang, G. W., Wang, H., Ma, J. X., Lan, X. Z., Liao, Z. H., et al. (2016). Herpetolide C: one new 7H-dibenzo[c,e]oxepin-5-one from *Herpetospermum* caudigerum. Acta Pharm. Sin. 51 (5), 770–774. doi:10.16438/j.0513-4870.2015-0938

Fang, Q. M., Zhang, H., and Cao, Y. (2008). Anti-oxidant activities of the seed extracts of *Herpetospermum pedunculosum* against liver injury in rats. *West China J. Pharm. Sci.* 02, 147–149. doi:10.13375/j.cnki.wcjps.2008.02.007

Fang, Q. M., Zhang, H., Cao, Y., and Wang, C. (2007). Anti-inflammatory and free radical scavenging activities of ethanol extracts of three seeds used as "Bolengguazi". *J. Ethnopharmacol.* 114 (1), 61–65. doi:10.1016/j.jep.2007.07.024

Feng, X., Li, M. H., Xia, J., Deng Ba, D. J., Ruan, L. Y., Xing, Y. X., et al. (2018b). Tibetan medical formula Shi-Wei-Gan-Ning-Pill protects against carbon tetrachlorideinduced liver fibrosis-an NMR-based metabolic profiling. *Front. Pharmacol.* 9, 965. doi:10.3389/fphar.2018.00965

Feng, X., Zhong, G. J., Deng Ba, D. J., Yang, B., Chen, L. Y., and Du, Y. (2018a). Hepatoprotective effect of *Herpetospermum caudigerum* Wall. on carbon tetrachloride-induced hepatic fibrosis in rats. *J. Cell. Mol. Med.* 22 (07), 3691–3697. doi:10.1111/jcmm.13568

Flora Reipublicae Popularis Sinicae Commission (1983). Flora Reipublicae Popularis Sinicae. Beijing: Science Publishing House.

Gong, F. Q. (2013). Studies on chemical constituents and pharmacological activity of the seeds of Herpetospermum caudigerum Wall. Master. Shandong: Shandong University of Traditional Chinese Medicine.

Gong, P. Y., Yuan, Z. X., Gu, J., Tan, R., Li, J. C., Ren, Y., et al. (2016). Anti-HBV activities of three compounds extracted and purified from Herpetospermum seeds. *Molecules* 22 (1), 14. doi:10.3390/molecules22010014

Hu, S. (2016). Study on the chemical constitutions of the ethyl acetate extract from Herpetospermum caudigerum. Master. Shandong: Southwest Jiaotong University.

Huang, D., Ma, Y. X., Wei, L., Sun, Y., Zeng, Q. H., Lan, X. Z., et al. (2021). One new coumarin from seeds of *Herpetospermum pedunculosum*. *China. J. Chin. Mater. Med.* 46 (10), 2514–2518. doi:10.19540/j.cnki.cjcmm.20210125.601

Huang, S. Y., Gu, J., Tan, R., Shi, Y. C., Liu, W., and Shi, L. L. (2018). The protective effect and mechanism of total lignans from Tibetan medicinal *Herpetospermum pedunculosum* seeds on chronic alcohol-induced hepatic injury in rats. *J. Chin. Med. Mater.* 41 (02), 432–436. doi:10.13863/j.issn1001-4454.2018.02.041

Huang, S. Y., Sun, N. Y., Sun, W., Fu, X. H., and Gu, J. (2017). Protective effect and mechanism of total lignans from Tibetan medicinal Herpetospermum seeds on alcoholinducing acute hepatic injury in mice. *China J. Chin. Mater. Med.* 33, 66–70. doi:10. 13412/j.cnki.zyyl.2017.05.018

Jiang, H. Z., Hu, S., Tan, R. X., Tan, R., and Jiao, R. H. (2020). Neocucurbitacin D, a novel lactone-type norcucurbitacin as xanthine oxidase inhibitor from *Herpetospermum pedunculosum*. *Nat. Prod. Res.* 34 (8), 1728–1734. doi:10.1080/14786419.2018.1528592

Jiang, H. Z., Tan, R., Jiao, R. H., Deng, X. Z., and Tan, R. X. (2016). Herpecaudin from *Herpetospermum caudigerum*, a xanthine oxidase inhibitor with a novel isoprenoid scaffold. *Planta. Med.* 82 (11-12), 1122–1127. doi:10.1055/s-0042-108210

Jiang, X. (2011). Protective effect of extracting solution of the Tibetan medicine Herpetospermum caudigerum seeds on acute liver injury mice produced by carbon tetrachloride. Master. Hubei: Huazhong Agricultural University.

Jin, S. Y., Li, R. S., Shen, B. D., Bai, J. X., Xu, P. H., Dai, L., et al. (2016). Lignans-rich extract from Herpetospermum caudigerum alleviate physical fatigue in mice. *Chin. J. Integr. Med.* 22 (11), 840–845. doi:10.1007/s11655-016-2254-2

Kaouadji, M., and Favre-Bonvin, J. (1984). Herpetol, a new dimeric lignoid. from Herpetospermum caudigerum Wall. Z. Naturforsch., C. J. Biosci. 39, 307–308. doi:10. 1515/znc-1984-3-419

Kaouadji, M., and Jean, F. B. (1983). Herpetrione, lignoide trimere isoled'Herpetospermum caudigerum. *Tetrahedron Lett.* 24, 5881–5884. doi:10.1016/S0040-4039(00)94226-6

Kaouadji, M., Jean, F. B., and Mariotte, A. M. (1978). Herpetal, benzofuranne isolede *Herpetospermum caudigerum. Phytochemistry* 17, 2134–2135. doi:10.1016/s0031-9422(00)89299-7

Kaouadji, M., Jean, F. B., and Mariotte, A. M. (1979). Herpetriol and Herpetetrol, new lignoids isolated from Herpetospermum caudigerum Wall. Z. Naturforsch., C. J. Biosci. 34, 1129–1132. doi:10.1515/znc-1979-1208

Kaouadji, M., Jean, F. B., Sarrazin, F., and Davoust, D. (1987). Herpetetrone, another tetrameric lignoid from *Herpetospermum caudigerum* seeds. J. Nat. Prod. 50, 1089–1094. doi:10.1021/np50054a013

Kaouadji, M., and Pieraccini, E. (1984a). Herpetetradione, nouveau lignoide tetramere isoled'Herpetospermum caudigerum wall. *Tetrahedron Lett.* 25, 5135–5136. doi:10.1016/s0040-4039(01)81544-6

Kirsch, G., Abdelwahab, A. B., and Chaimbault, P. (2016). Natural and synthetic coumarins with effects on inflammation. *Molecules* 21, 1322. doi:10.3390/molecules21101322

Kong, F. M., Wang, C. R., Zhao, L. L., Liao, D. Y., Wang, X. Q., Sun, B. X., et al. (2023). Traditional Chinese medicines for non-small cell lung cancer: therapies and mechanisms. *Chin. Herb. Med.* 15 (4), 509–515. doi:10.1016/j.chmed.2023.05.004

Li, C. Q., Wang, Z. Y., Tang, H. J., Wang, C. D., and Zhang, M. (2015a). Protective effects of Herpetospermum polysaccharide on immunological liver injury induced by concanavalin A in mice. *Pharmacol. Clin. Chin. Mater. Med.* 31 (04), 94–97. doi:10. 13412/j.cnki.zyyl.2015.04.029

Li, G., Wang, X. Y., Suo, Y. R., and Wang, H. L. (2014). Protective effect of seed oil of *Herpetospermum pedunculosum* against carbon tetrachloride-induced liver injury in rats. *Saudi Med. J.* 35 (9), 981–987.

Li, J., Lu, Q., Peng, M., Liao, J., Zhang, B., Yang, D., et al. (2023). Water extract from Herpetospermum pedunculosum attenuates oxidative stress and ferroptosis induced by acetaminophen via regulating Nrf2 and NF- κ B pathways. J. Ethnopharmacol. 305, 116069. doi:10.1016/j.jep.2022.116069

Li, J. J., Cheng, L., Shen, G., Qiu, L., Shen, C. Y., Zheng, J., et al. (2018). Improved stability and oral bioavailability of Ganneng dropping pills following transforming lignans of *Herpetospermum caudigerum* into nanosuspensions. *Chin. J. Nat. Med.* 16 (1), 70–80. doi:10.1016/S1875-5364(18)30031-1

Li, L. Y., Shu, S., Wei, Y. F., Zhong, G. Y., and Chen, J. H. (2005). Morphological and histological studies of *Herpetospermum pedunculosum* seeds and other substitutes. *China J. Chin. Mater. Med.* 14, 1073–1076.

Li, M. H., Feng, X., Deng Ba, D. J., Chen, C., Ruan, L. Y., Xing, Y. X., et al. (2019). Hepatoprotection of *Herpetospermum caudigerum* Wall. against CCl₄-induced liver fibrosis on rats. *J. Ethnopharmacol.* 229, 1–14. doi:10.1016/j.jep.2018.09.033

Li, N. Z., Shi, Y. W., Guo, M. X., Zhu, J. X., Liang, J., and Feng, Y. L. (2023). Study on protective effect and mechanism of total lignans from Tibetan medicine *Herpetospermun caudigerum* Wall against α-Naphthylisothiocyanate-induced liver injury in mice. *Tradit. Chin. Drug Res. Clin. Pharmacol.* 34 (01), 49–56. doi:10. 19378/j.issn.1003-9783.2023.01.007

Li, Y. L., Zhou, F. C., Wang, H. L., Ding, C. X., and Suo, Y. R. (2005). Analysis of amino acids in Tibetan medicine. *Herpetospermum penduculosum Biot. Resour.* 04, 11–12.

Liao, J. Q. (2023). Molecular mechanism research of ethanol extract of Herpetospermum pedunculosum *seeds* alleviating acetaminophen-induced liver injury. Master. Sichuan: Chengdu University.

Ling, H. L., Liu, M. L., and Zhang, M. (2018). Simultaneous determination of four fatty acids in the fatty oil from Bolenggua seeds by GC-MS. Asia-Pacific Tradit. Med. 14, 37–40.

Liu, F., Zhu, M. Q., and Liu, W. Y. (2022). Hepatoprotective effects of total sterols from *Herpetospermum caudigerum* Wall. shell on CCl₄-induced acute liver injury in

mice and quantification of major ingredients by RP-HPLC. World Sci. Technology-Modernization Traditional Chin. Med. 24, 2319–2330.

Liu, J., Chen, X., Zhang, Y., and Zhang, M. (2010). Chemical constituents of the ethyl acetate extract from Semen herpetospermi. *Pharmacol. Clin. Chin. Mater. Med.* 1 (03), 15–18.

Liu, M. L. (2017a). Primary studies on the methods for quality control and liver injury of active fractions of Herpetospermum caudigerum. Master. Sichuan: Chengdu University of Traditional Chinese Medicine.

Liu, S. Y. (2017b). Study on the protective effect and mechanism of herpetin, an effective component of Tibetan medicine Herpetospermum caudigerum Wall, on immune liver injury. Master. Sichuan: Southwest Minzu University.

Liu, W., Fu, X. H., Huang, S. Y., Shi, Y. C., Shi, L. L., and Gu, J. (2017a). Protective effect and mechanism of total lignans from Herpetospermum seeds on carbon tetrachloride-induced liver fibrosis in rats. *China J. Chin. Mater. Med.* 42 (3), 567–571. doi:10.19540/j.cnki.cjcmm.20161222.063

Liu, X. L., Han, Y. P., Xu, X. S., and Song, X. W. (2005). Analysis of fat oil from Bolenggua seeds by GC-MS. J. Southwest Univ. Nat. Sci. 05, 710–711.

Luo, D. S. (1997). Chinese Tibetan medicine. Beijing: Minzu press.

Ma, Y. X. (2020). Study on the chemical constitutions of the ethyl acetate extract from Herpetospermum pedunculosum. Master. Sichuan: Southwest University.

Meng, F. C., Ma, Y. X., Zhan, H. H., Zong, W., Linghu, L., Wang, Z., et al. (2022). Lignans from the seeds of *Herpetospermum pedunculosum* and their farnesoid X receptor-activating effect. *Phytochemistry* 193, 113010. doi:10.1016/j.phytochem. 2021.113010

Patel, D. K. (2021). Pharmacological activities and therapeutic potential of kaempferitrin in medicine for the treatment of human disorders: a review of medicinal importance and health benefits. *Cardiovasc Hematol. Disord. Drug Targets* 21 (2), 104–114. doi:10.2174/1871529X21666210812111931

Qian, Y. Z., Han, J., Liu, L. P., Zhang, Y. Y., Guo, J. J., and Yuan, H. L. (2011). Determination of Herpetrione in *Herpetospermum caudigerum* by ultrahigh performance liquid chromatography. *Pharm. J. Chin. People's Lib. Army.* 27, 527–528+531.

Shen, B., Chen, H. G., Shen, C. Y., Xu, P. H., Li, J. J., Shen, G., et al. (2015). Hepatoprotective effects of lignans extract from *Herpetospermum caudigerum* against CCl₄-induced acute liver injury in mice. *J. Ethnopharmacol.* 164, 46–52. doi:10.1016/j. jep.2015.01.044

Shen, G., Chen, L., Wang, L. Q., Zhong, L. H., Shen, B. D., Liao, W. B., et al. (2016). Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability. *Chin. J. Nat. Med.* 14 (10), 757–768. doi:10.1016/S1875-5364(16)30090-5

Wang, H. (2005). Studies on the chemical components in bioactive part and HPLC fingerprint of the Tibetan medicinal substance Herpetospermum seed. Master. Sichuan: Chengdu University of Traditional Chinese Medicine.

Wang, L., Liu, S. Y., Sun, N. Y., Li, J. C., and Gu, J. (2016). Protection of herpetin from Tibetan medicine Herpetospermum seeds on ConA-induced immunologic liver injury in mice. J. Southwest Univ. Nat. Sci. 42, 492–495.

Wang, L. X., Wang, H. L., Huang, J., Chu, T. Z., Peng, C., Zhang, H., et al. (2022a). Review of lignans from 2019 to 2021: newly reported compounds, diverse activities, structure-activity relationships and clinical applications. *Phytochemistry* 202, 113326. doi:10.1016/j.phytochem.2022.113326

Wang, P. L. (2014). Research on quality control of the seeds of Herpetospermum pedunculosum (Sex.). Master. Chongqing: Southwest University.

Wang, S. W., Li, Y. X., Du, C. Y., Fan, H. B., Wu, X. Q., Chen, X., et al. (2022b). Chemical constituents, anti-hyperuricemic and anti-gouty arthritis activities of extract of *Herpetospermum caudigerum*. *Pharmacol. Res.* 3, 100102. doi:10.1016/j.prmcm.2022. 100102

Wei, X. D. (2020). Study on FXR-mediated anti-cholestasis effect and mechanism of the seeds of Herpetospermum pedunculosum. Master. Chongqing: Southwest University.

Wei, X. D., Fan, X. D., Feng, Z. Y., Ma, Y. X., Lan, X. Z., and Chen, M. (2020). Ethyl acetate extract of *Herpetospermum pedunculosum* alleviates α-naphthylisothiocyanateinduced cholestasis by activating the farnesoid x receptor and suppressing oxidative stress and inflammation in rats. *Phytomedicine* 76, 153257. doi:10.1016/j.phymed.2020. 153257

Wu, Y., Xu, J., Liu, Y. T., Zeng, Y. Y., and Wu, G. J. (2020). A review on anti-tumor mechanisms of coumarins. *Front. Oncol.* 10, 592853. doi:10.3389/fonc.2020.592853

Xiao, S. L., Tian, Z. Y., Wang, Y. F., Si, L. L., Zhang, L. Z., and Zhou, D. M. (2018). Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. Med. Res. Rev. 38 (3), 951-976. doi:10.1002/med. 21484

Xu, B. (2012). Studies on the chemical constituents of Herpetospermum caudigerum Wall. Master. Chongqing: Southwest University.

Xu, B., Liu, S., Fan, X. D., Deng, L. Q., Ma, W. H., and Chen, M. (2015). Two new coumarin glycosides from *Herpetospermum caudigerum*. J. Asian Nat. Prod. Res. 17 (7), 738–743. doi:10.1080/10286020.2014.996137

Xu, W. H., Zhao, P., Wang, M., and Liang, Q. (2019b). Naturally occurring furofuran lignans: structural diversity and biological activities. *Nat. Prod. Res.* 33 (9), 1357–1373. doi:10.1080/14786419.2018.1474467

Xu, X., Lu, H. G., Xie, X., Liu, Y. T., Zhao, H. Q., Lei, C., et al. (2023). Ershiwuwei Songshi Pills improve CCL₄-induced liver fibrosis in rats by regulating macrophage phenotype. *Pharmacol. Clin. Chin. Mater. Med.* 39, 17–23. doi:10.13412/j.cnki.zyyl. 20230525.002

Xu, X. Y., Wang, D. Y., Li, Y. P., Deyrup, S. T., and Zhang, H. J. (2022). Plant-derived lignans as potential antiviral agents: a systematic review. *Phytol. Clin. Chin.Mater.Med.* 21 (1), 239–289. doi:10.1007/s11101-021-09758-0

Xu, Z., Zhao, S., Lv, Z., Feng, L., Wang, Y., Zhang, F., et al. (2019a). Benzofuran derivatives and their anti-tubercular, anti-bacterial activities. *Eur.J. Med. Chem.* 162, 266–276. doi:10.1016/j.ejmech.2018.11.025

Yang, B., Luo, Q. L., Wang, N., Hu, Y. T., Zheng, W. X., Li, H., et al. (2023). HPF modulates the differentiation of BMSCs into HLCs and promotes the recovery of acute liver injury in mice. *Int. J. Mol. Sci.* 24 (6), 5686. doi:10. 3390/ijms24065686

Yang, F., Zhang, H. J., Zhang, Y. Y., Chen, W. S., Yuan, H. L., and Lin, H. W. (2010). A hepatitis B virus inhibitory neolignan from *Herpetospermum caudigerum. Chem. Pharm. Bull.* 58 (3), 402–404. doi:10.1248/cpb.58.402

Yu, J. Q., Hang, W., Duan, W. J., Wang, X., Wang, D. J., and Qin, X. M. (2014). Two new anti-HBV lignans from Herpetospermum caudigerum. *Phytochem. Lett.* 10, 230–234. doi:10.1016/j.phytol.2014.10.001

Yuan, H. L. (2006a). Extracts from *Herpetospermum caudigerum* Wall, their Dropping Pills, preparation methods, and applications. Patent. No: CN1857367A.

Yuan, H. L., Guo, J. J., Li, X. Y., Han, J., Lv, J. L., and Fu, S. S. (2011). Preparation and application of herperione and its capsule. Patent. No: CN102140101A.

Yuan, H. L., Liu, Y., Zhao, Y. L., and Xiao, X. H. (2005). Herpetin, a new bioactive lignan isolated from *Herpetospermum caudigerum*. J. Chin. Pharm. Sci. 03, 140–143.

Yuan, H. L., Yang, M., Li, X. Y., You, R. H., Liu, Y., Zhu, J., et al. (2006b). Hepatitis B virus inhibiting constituents from *Herpetospermum caudigerum*. *Chem. Pharm. Bull.* 54 (11), 1592–1594. doi:10.1248/cpb.54.1592

Yuandan, K., and Song, T. (1987). Si Bu Yi dian. Shanghai: Shanghai Science and Technology Press.

Zhang, M., Deng, Y., Zhang, H. B., and Chen, H. L. (2007). Herpetolide, preparation method and application. Patent. No: CN101311173.

Zhang, M., Deng, Y., Zhang, H. B., Su, X. L., Chen, H. L., Yu, T., et al. (2008). Two new coumarins from *Herpetospermum caudigerum*. *Chem. Pharm. Bull.* 56, 192–193. doi:10. 1248/cpb.56.192

Zhang, M., Dong, X. P., Deng, Y., Wang, H., Li, X. N., and Song, Q. (2006). A new sesqui-norlignan from *Herpetospermum pedunculosum. Acta Pharmacol. Sin.* 41 (07), 659–661. doi:10.16438/j.0513-4870.2006.07.015

Zhang, M., Dong, X. P., Wang, H., Li, X. N., and Song, Q. (2004). GC-MS analysis on the fatty oils of the Tibetan medicinal substance Herpetospermum. *J. Chengdu Univ. Tradit. Chin. Med.* 04, 49–52.

Zhang, Y., Lin, S., Peng, J., Liang, X., Yang, Q., Bai, X., et al. (2022). Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. *Mol. cell* 82 (8), 1528–1542.e10. doi:10.1016/j.molcel.2022.01.021

Zhao, X. E., Liu, R. J., Wang, H. L., and Su, Y. R. (2009). HPLC and GC-MS analysis of fatty acids Tibetan medicine Herpetospermum seed oil. *Nat. Prod. R&D.* 21 (01), 76–83. doi:10.16333/j.1001-6880.2009.01.022

Zhao, X. R., Zhang, L., Li, J. C., and Gu, J. (2015). Protective effect of total lignans from Tibetan medicinal Herpetospermum seeds on experimental liver injury by CCl₄. *J. Southwest Univ. Nat. Sci.* 41 (02), 181–185.

Zhong, Y., Zhang, B. W., Li, J. T., Zeng, X., Pei, J. X., Zhang, Y. M., et al. (2023). Ethanol extract of *Herpetospermum caudigerum* Wall ameliorates psoriasis-like skin inflammation and promotes degradation of keratinocyte-derived ICAM-1 and CXCL9. *J. Integr. Med.* 21 (6), 584–592. doi:10.1016/j.joim.2023.11.004

Zhou, X. S. (2014). Systematic study on the lignans compounds of Herpetospermum caudigerum. Master. Sichuan: Southwest Jiaotong University.